University of Texas at El Paso

DigitalCommons@UTEP
Open Access Theses & Dissertations

2018-01-01

The Structural And Functional Study Of The
Human Mitochondrial Hsp60 Chaperonin In
Neurodegenerative Diseases
Jinliang Wang
University of Texas at El Paso, wangjinliangwz@126.com

Follow this and additional works at: https://digitalcommons.utep.edu/open_etd
Part of the Biochemistry Commons
Recommended Citation
Wang, Jinliang, "The Structural And Functional Study Of The Human Mitochondrial Hsp60 Chaperonin In Neurodegenerative
Diseases" (2018). Open Access Theses & Dissertations. 20.
https://digitalcommons.utep.edu/open_etd/20

This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations
by an authorized administrator of DigitalCommons@UTEP. For more information, please contact lweber@utep.edu.

THE STRUCTURAL AND FUNCTIONAL STUDY OF THE HUMAN MITOCHONDRIAL
HSP60 CHAPERONIN IN NEURODEGENERATIVE DISEASES

JINLIANG WANG
Doctoral Program in Chemistry

APPROVED:

Ricardo A Bernal, Ph.D., Chair

Chu Young Kim, Ph.D.

Xiujun Li, Ph.D.

Jianying Zhang, Ph.D.

Sudheer Molugu, Ph.D.

Jay M. Bhatt, Ph.D.

Charles Ambler, Ph.D.
Dean of the Graduate School

Copyright ©

by
Jinliang Wang
2018

Dedication

This dissertation is dedicated to my teachers and my family. All my achievements would
not have been reached without their support.

THE STRUCTURAL AND FUNCTIONAL STUDY OF THE HUMAN MITOCHONDRIAL
HSP60 CHAPERONIN IN NEURODEGENERATIVE DISEASES

by

JINLIANG WANG, MS

DISSERTATION

Presented to the Faculty of the Graduate School of
The University of Texas at El Paso
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHILOSOPHY

Department of Chemistry and Biochemistry
THE UNIVERSITY OF TEXAS AT EL PASO
December 2018

Acknowledgements
I would like to express my sincere gratitude to my advisor Dr. Ricardo Bernal for
providing me a chance to do the structural research and for the continuous support
during my PhD studies at the University of Texas at El Paso (UTEP). It has been a
tremendous honor to work with Dr. Bernal. His motivation, enthusiasm, immense
knowledge, and humor impressed me and encouraged me during my PhD study. He
shared his time, patience, and wisdom to support me for the structural biology study. I
still remembered that he spent a lot of time helping me to correct my poster. His
enthusiasm and dedication for research will inspire me in my postdoc training. I would
also like to extend my deepest gratitude to my committee members; Dr. Chu Young
Kim, Dr. Xiujun (James) Li, Dr. Jianying Zhang, Dr. Sudheer Molugu, and Dr. Jay Bhatt
for investing their time and patience to ensure my growth in academia.
I also would like to thank my colleagues in Bernal group, past and present, for
their encouragement and support. I still remembered all the days with them. I like to
thank Bianka for always encouraging me, Alex for sharing the soccer games together,
Adrian for teaching me Eman2 software, Jay for correcting my dissertation, Janelly for
correcting my proposals, and Humberto, Karen, Jihui, Maria, Daniel and all the
undergraduates.
Finally, I would like to thank my family and friends who have supported me
throughout my academic career. Without my parents’ financial support and
encouragement, I would not have made it through my PhD tenure. Special thanks to my
wife, Yuxin Wen for understanding my unavailability and sharing happiness and sorrow
all through my life.
v

Abstract
Proteins are essential elements that are responsible for a variety of cellular
activities within organisms, including catalyzing metabolic reactions, DNA replication,
responding to stimuli, providing structure to cells and organisms, and transporting
molecules. After protein synthesis in the ribosome, the unfolded protein need to fold into
their unique compact structures so that they can perform their full biological functions.
The biologically active structure of a protein is referred to the native-state of the protein
with biological activity. The process of protein folding is one of the most important and
challenging research topics of contemporary biochemistry, especially for its central role
in life. The folding of polypeptide chains into their unique three-dimensional structure is
of fundamental importance in biology. Chaperonins are a class of proteins that
assemble into barrel-shaped chamber to renature the misfolded, non-functional proteins
to the folded, functional state.
The human mitochondrial heat shock protein 60 (hsp60) functions as a
chaperonin, folding proteins in the human mitochondrial matrix. D3G and V72I point
mutations in Hsp60 have been shown to lead to the neurodegenerative disorders
MitCHAP-60 and SPG13, respectively. A D3G mutation in hsp60 leads to MitCHAP-60,
an early onset neurodegenerative disease characterized by muscle weakness, limb
spasticity and involuntary eye movement. Another hsp60 mutation, V72I, has been
linked with SPG13, a form of hereditary spastic paraplegia, characterized by
progressive weakness, spasticity in the lower limbs, impaired vision, deafness, and
cognitive impairment. There are no specific treatments to prevent, slow, or reverse
these two diseases. The detailed mechanism of the two diseases are also unknown.

vi

The -subunit of the human mitochondrial ATP synthase has been coimmunoprecipitated together with the Hsp60 indicating that the β-subunit is likely being
folded by the chaperonin. The biological effects of the interaction have not been studied
but we hypothesize that the lack of active β-subunit is the cause of the neurological
disorders. We expressed and purified recombinant wild type and mutant hsp60
complexes and analyzed them via electron microscopy, dynamic light scattering (DLS),
and in-vitro protein-folding assays. We characterized the wild type hsp60 conformational
changes upon nucleotide binding and postulate a likely catalytic cycle with the various
conformational intermediates. Negative-stain electron microscopy along with DLS
suggest that the D3G and V72I complexes fall apart when treated with ATP or ADP and
are therefore unable to fold denatured substrates such as α-lactalbumin, malate
dehydrogenase (MDH), and the -subunit of ATP synthase. Our data suggests that
hsp60 plays a crucial role in folding important players in aerobic respiration such as the
-subunit of the ATP synthase and MDH. D3G and V72I mutations in hsp60 impair its
ability to fold these substrates leading to abnormal ATP synthesis and the MitCHAP-60
and SPG13 neurodegenerative disorders. These studies indicate that that hsp60 is
important for folding members of mitochondrial energy producing pathways such as the
ATP synthase -subunit or malate dehydrogenase. Mutations that lead to inactive
Hsp60 complexes indirectly lead to MitCHAP-60 and SPG13.
The hydrophobic flexible C-terminal end of each subunit in the hsp60 chaperonin,
protrudes inside the central cavity. The central cavity is the place where the protein
folding cycle happens. We generated and characterized E. coli strains expressing
Hsp60 C-terminus deletion chaperonin protein to study the hsp60 protein folding cycle.

vii

If the C-terminus deletion of hsp60 chaperonin impaired the interaction between
neighboring subunits, the yeast strains will dead. Researchers have showed that the Cterminus deletion hsp60 chaperonin remained capable of the binding activity with the
cochaperonin hsp10 in the nucleotide-dependent manner. By generating the C-terminus
26 amino acid deletion (CTD) hsp60, we try to explain the mechanism of the hsp60
chaperonin protein folding cycle with the unfolded substrates or the folded, unreleased
substrates by the protein reconstruction analyze. We found that the protein folding
activity of the hsp60-MDH is much lower than the hsp60 wildtype, even hsp60-CTD can
still form the complex. We also found the hsp60-CTD binds the denatured malate
dehydrogenase (MDH) by using the native gel and dynamic light scattering.
Keywords: MitCHAP-60, Hereditary Spastic Paraplegia, SPG-13, Hsp60, Chaperonin,
Protein folding, ATP Synthase β-Subunit, Neurodegeneration.
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Chapter 1: Background and Introduction
1.1 Protein folding
Proteins are essential elements that are responsible for a variety of cellular
activities within organisms, including catalyzing metabolic reactions, DNA replication,
responding to stimuli, providing structure to cells and organisms, and transporting
molecules.[1] After protein synthesis in the ribosome, they need to fold into their unique
compact structures so that they can perform their full biological functions.[2] The nativestate structure of a protein is the protein that can perform full biological functions. In
some instances, multiple proteins can interact with each other to form larger quaternary
structural complexes to get a fully biologically active conformation.[3]
The process of protein folding is one of the important, challenging, most studied
research topics of contemporary biochemistry, especially for its central role in life. [4]
The folding of polypeptide chains into their unique three-dimensional structures is of
fundamental importance in biology. Understanding the protein folding process will
provide a unique insight into the way in which evolutionary selection has influenced the
properties of a molecular system for functional advantage.[5] The mechanism of protein
folding cycle is also one of the most challenging ,and the least understood biophysical
research topics. The major milestone of protein folding research was the
thermodynamic hypothesis by Christian Anfinsen.[6] Protein folding mechanisms were
first studied in vitro using purified, chemically denatured polypeptides as unfolded
substrates in 1973 by Christian Anfinsen. According to Anfinsen’s famous experiments
on ribonuclease study, he demonstrated that the native structure of a protein depends
on the amino acid sequence, and the solution conditions instead of the kinetic folding
pathway.[5] According to Anfinsen, the resulting three-dimensional protein structure is
determined by the amino acid sequence (the primary structure of the protein), which is
also called Anfinsen's dogma. The importance of the primary structure for defining the
1

native structure of protein was discovered when the sequence of hemoglobin gene was
subjected to point mutation.[7] This point mutation in the hemoglobin led to devastating
consequences in folding and functions in the fundamental metabolism inside cells,
leading to sickle-cell anemia disease (SCD) which is a group of blood disorders[8].
Moreover, cystic fibrosis[9], the prion diseases[10], Huntington’s disease[11],
Parkinson’s disease[12], and Amyotrophic lateral sclerosis (ALS)[13] are also known to
be associated with mutations in amino acid sequence of other proteins.
Based on Anfinsen’s work, researchers have come to understand native
structures by using test tubes in vitro rather than the inside cells in vivo, which makes
protein folding research study much easier. However, the concept of the spontaneous
protein folding cannot be extrapolated to living cells in-vivo, which is a huge difference
from the process in-vitro. The big difference between the ideal circumstances used invitro refolding studies and those encountered in-vivo is that the intracellular environment
is highly crowded because of the presence of high concentrations of soluble and
insoluble macromolecules, which was estimated at 170-400 mg/ml within the cell
nucleus.[14]
The correct three-dimensional protein structure is essential to the protein
function properly, for that case, protein conformation dynamics is very important for the
life. [15] Failure to fold into native functional protein structure generally can generate
inactive protein conformation, which may cause many serious diseases. The misfolded
proteins can form the accumulation of amyloid fibrils which may cause several
neurodegenerative disorder diseases and other diseases.[16] Many allergies are also
caused by incorrect folding of correct protein structures, because of the immune system
does not produce antibodies for certain correct protein structures.[17] Many intracellular
factors including biophysical phenomena induced by the polar solvent, molecular
chaperones, and specialized macromolecular complexes termed chaperonins have
contribution to the protein folding process into a native correct three-dimensional
2

structure.[18] In fact, not all the proteins need the assistance of chaperonins to generate
the correct functional 3D structure. It is estimated that about 10%-30% of all cellular
proteins require the assistance of a chaperonin to fold properly into their correct
functional 3D structure.[6, 11, 18-20]
1.2 Chaperonin
Living organisms have developed mature systems of preventing the misfolding
and aggregation of newly synthesized proteins and for controlling the folding status of
polypeptides.[21] These functions are fulfilled by molecular chaperonins. Chaperonins
prevent inappropriate inter- and intra-molecular interactions by binding to hydrophobic
patches of non-native proteins, thereby influencing the partitioning between productive
and unproductive folding pathways.[22] Importantly, chaperonins usually do not form
part of the final confirmation of the folded proteins.[23] The folded substrates are
released from the chaperonins chamber, thereby providing non-native proteins with a
new opportunity for productive folding cycle. Some chaperonins perform an ATPdependent mode of substrate interaction (Hsp100, Hsp90, Hsp70, Hsp60), while others
(TF, sHsps) do not need ATP nucleotides to perform the protein folding cycle.[24]
Finally, depending on their abilities to either prevent protein aggregation or to support
proper protein (re)folding, chaperonins can be classified into two groups: ‘holder’
chaperonin and ‘folder’ chaperonins.[25] Holder chaperonins and folder chaperonins
may also functionally cooperate to perform the chaperonin folding activities.
Based on the requirement of a co-chaperonin and subunit heterogeneity,
chaperonins are usually categorized into two groups, group I chaperonin and group II
chaperonin.[26, 27] Group I chaperonins (Figure.1.1), which need a co-chaperonin to
perform the protein folding activity, are homo-oligomers with seven subunits in each of
two rings arranged back to back.[26-28]. Group I chaperonin is the most studied
chaperonin group (e.g., Escherichia coli GroEL/ES) for which the general mechanism of
3

chaperonin-mediated protein folding cycle was first described[26-28]. The group II
chaperonins, which do not need the co-chaperonin for the catalytic cycle, are homo- or
hetero-oligomers with eight or nine subunits per ring.[29] [30] The classic group II
chaperonins are the thermosome, Mm-cpn, TF55, and TriC. Unlike group I chaperonins,
the apical domains in group II chaperonins are rearranged to form protrusions that
extend to form an iris-like structure that closes the cavity entrance after the hydrolysis of
ATP, for that case, group II chaperonins do not need the co-chaperonin to perform the
chaperonin activities [31].
The protein folding mechanism of the molecular chaperones is that the chaperonin
firstly specifically binds non-native unfolded states of proteins through exposed
hydrophobic subunits that eventually become buried to the interior in the native functional
state, effectively forestalling the aggregation. [32] The chaperonin protein folding catalytic
cycle need the ATP hydrolysis as the energy source to release the bound folded
substrates for another attempt protein folding cycle.[32, 33] For some chaperonin, the
change of the chaperonin conformation needs the step of binding and/or release, either
nucleotides or unfolded substrates, while in some chaperonin, the chaperonin
conformation change does not need the binding/releasing step. The whole purpose of the
protein folding cycle is protecting the protein from misfolding and aggregation, to keep the
biological activity. The different chaperonins have different topologies of binding different
substrates with or without nucleotides.[34] Hsp70 chaperonin system binds to the
extended peptide segments of proteins as well as partially folded proteins whose exposed
hydrophobic side-chains to prevent aggregation, remodel folding pathways, and regulate
activity.[35]
1.2.1 GroEL Chaperonin
GroEL chaperonin ,the most studied classic group I chaperonin, is a
tetradecamer of identical 57 kDa subunits, arranged in two heptameric subunits stacked
4

back-to-back with a central cavity in each ring [36](Figure. 1.1). Each subunit of the
GroEL chaperonin comprises three domains: equatorial domain, apical domain, and
intermediate domain.[36] The equatorial domain, which contains the ATP nucleotides
binding pocket ,can bind ADP or ATP nucleotides and provide the inter-ring contacts to
hold the two ring subunits together. The apical domain has the hydrophobic surface at
the entrance to the cavity that interacts with the unfolded polypeptide as well as the cochaperonin, GroES. The intermediate domain has flexible hinges at each end that
permit the large -scale domain movements during protein folding cycle. The GroES, the
co-chaperonin of GroEL, is a single-ring heptamer of identical 10 KDa molecular weight
subunits that binds to GroEL in the presence of nucleotides[37], capping one cavity of
the GroEL to form an asymmetric bullet complex, or capping two cavities of the GroEL
to form a symmetric American football complex. The binding and releasing step of
GroES is a dynamic step during the protein folding reaction cycle.

Figure 1.1 General Architecture of GroEL Chaperonin
A. Side view of the bacterial groEL cylindrical cochaperonin complex without co-chaperonin
groES; Cis: The active folding ring with substrate proteins bound into it. Trans: the opposite ring
without client proteins binding into it; B: three domains that construct the groEL subunit was
labeled with three different colors, equatorial domain (cyan,) intermediate domain (yellow),
apical domain (pink).[38]

5

The GroEL chaperonin folding cycle is starting with the binding of the ATP
nucleotides to the nucleotides binding pocket of an open GroEL chaperonin ring which
will make the shape slightly changed to get ready for the binding step of a non-native
unfolded substrates as well as the cochaperonin GroES. After ATP nucleotides binding,
the non-native unfolded substrates will get into the GroEL chamber. The cochaperonin
GroES will bind to the same ring which will switch the chaperonin ring from open state
to a closed, folding-active state. At the meantime, the surface of the GroEL chaperonin
will convert by rigid-body movements from hydrophobic state to hydrophilic state. There
are three major features of the cis GroEL-GroES protein complex (double ring,
symmetric American football conformation, asymmetric bullet conformation) in the
GroEL chaperonin protein folding cycle. GroEL chaperonin bind only one unfolded
substrate molecular at a time.[39] Therefore, an unfolded polypeptide folding is this
encapsulated environment simply has no other species with which to form a
multimolecular aggregate. The hydrophilicity of the cavity lining is the second feature.
The switch to hydrophilic character upon ATP/GroES binding is involved in the ejection
of substrate off the cavity wall. The presence of a hydrophilic cavity can also assist the
protein productive folding since it favors burial of hydrophobic surfaces and exposure of
hydrophilic ones, properties of the native state, in the properties of the native state, in
the folding substrate protein. [32]Finally, the situation of confinement within a cavity may
limit the range of conformations that a non-native protein can explore. Fully extended
conformations would be excluded from forming inside a cavity. These latter properties
may serve to provide a novel and smoother environment to the energy landscape for a
polypeptide folding inside a GroEL-GroES cis complex.[40]

6

Figure 1.2 The Protein folding cycle of groEL/ES chaperonin complex. [38]
The protein folding cycle is initiated by ATP binding to the cis-ring in groEL that causes an
elevation of the apical domains. After the rise of the apical domains, substrate protein and
groES co-chaperonin protein can now associate with groEL through hydrophobic interactions.
The net effect is the encapsulation of substrate inside an isolated chamber with a hydrophilic
lining. Substrate folding, and ATP hydrolysis presumably happen simultaneously. Upon ATP
hydrolysis to ADP releases inorganic phosphate (Pi), the trans-ring is ready for the binding of
ATP, substrate and co-chaperonin. The subsequent binding of ATP to the trans-ring triggers
dissociation and ejection of groES and native-substrate from the cis-ring. The binding of ATP to
the opposite ring (trans) triggers the release of co-chaperonin groES and discharging of folded
substrate and the new cycle starts.

Given the assistance provided by the GroEL-GroES chaperonin system through
both the binding and the cis-folding steps, it is understandable that the outcome of
folding of its normal substrate proteins in the absence of chaperonin is not a productive
one. For example, in yeast systems with conditional deficiency of the mitochondrial
Hsp60 chaperonin, the GroEL homologue, the imported mitochondrial proteins will not
fold correctly, fail to reach the native functional state and result to insoluble aggregates,
which will make the yeast hard to survive[41, 42]. Without the aid of the chaperonin, the
diluted protein will aggregate and lose their biological functions in vitro. However, the
chaperonin will rescue the aggregation processing of the diluted protein. The unfolded
protein will be quantitatively transformed into the native folded functional conformation
with the help of the chaperonin, cochaperonin as well as the nucleotides. The
7

chaperonin knockout experiments in-vivo indicated that the action of chaperonins kinetic
assistance is essential for the cell viability under all temperature stress conditions.[37,
41] .
With the help of the development of the structural biology, researchers have
been able to partly explain the detailed mechanism of the GroEL-GroES chaperonin
folding cycle by analyzing the different conformational states. We will review here both
what is currently known about conformational states of substrates during the chaperonin
reaction and what the prospects are for a better understanding of the action of the
machine on them.
The bacterial chaperonin GroEL and its cochaperonin, GroES, form a nanochamber (symmetric American football, asymmetric bullet) for a single molecule of
unfolded substrate to fold into folded functional protein. GroEL and its co-chaperonin
GroES undergo an ATP-drive interaction rotation to close and open the folding chamber
to perform its protein folding activity. GroEL chaperonin consists of two heptameric rings
(tetradecamer) stacked back to back. Recently, a research group found that GroEL
undergoes transient ring separation, resulting in ring exchange between complexes.
Ring separation occurs upon ATP-binding to the trans ring of the asymmetric
GroEL:7ADP: GroES complex in the presence or absence of substrate protein and is a
consequence of inter-ring negative allostery. transient ring separation is an integral part
of the chaperonin mechanism.[43]

1.2.2 Mitochondrial Heat Shock Protein Hsp60
1.2.2.1 Structure and Function
Mitochondrial heat shock protein Hsp60 is a class of chaperone protein whose
primary function is the folding and assembly of unfolded polypeptide chains imported
into the mitochondrial matrix into the folded functional protein. Therefore, mitochondrial
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hsp60 chaperonin is highly important in mitochondrial protein folding cycle and quality
control function , especially when the cells are under the cellular stress conditions, such
as heat shock stress and hypoxia stress.[44] Mitochondrial hsp60 chaperonin protein is
encoded in the nucleus by a gene named HSPD1 and bears a 26 amino acid N-terminal
mitochondrial localization sequence (mitochondrial targeting sequence).[45] In order to
form mature mitochondrial hsp60 chaperonin which is mainly localized to the
mitochondrial matrix and outer membrane, the N-terminal mitochondrial localization
sequence (mitochondrial targeting sequence) is cleaved after transported into the
mitochondria from the cytoplasm.[46, 47]. The majority hsp60 chaperonin
(approximately 80%) is scattered throughout the mitochondria where it catalyzes the
protein folding cycle destined for the mitochondrial matrix. About 15-20% of hsp60
chaperonin is extramitochondrial, distributed among the cytosol, plasma membrane,
peroxisomes, and endoplasmic reticulum[48]. Mitochondrial hsp60 chaperonin is
constitutively expressed in both neuronal and non-neuronal tissues and up-regulated by
the cellular stress condition to rescue the cell survive.[49]. Hsp60 folding activity needs
the hydrolysis of ATP nucleotides as the energy source to perform the catalytic cycle
[44]. If the mitochondrial dysfunction and cannot generate enough ATP nucleotides, the
chaperonin hsp60 protein folding activity can be impaired, resulting in continuous
mitochondrial damage and eventually causing serious diseases, especially the
neurological disorder diseases. Hsp10, the co-chaperonin of the mitochondrial hsp60
chaperonin, is required to control the ATPase cycle for Hsp60-mediated folding of some
unfolded substrates[50].
Current researches have showed evidence that the hsp60 mitochondrial
chaperonin uses both single (asymmetric bullet conformation) and double-ring
conformations (symmetric American football conformation) in the hsp60 protein folding
cycle [51]. Researchers try to purify individual monomers to reassemble into oligomeric
9

complexes upon the addition of ATP nucleotides , but due to the instability of
mitochondrional hsp60 chaperonin in-vitro, it is very difficult to get the three-dimensional
oligomeric complex structure.[52] In 2015, a research group in Israel mutated the amino
acid glutamine into glutamic acid in 321 position of hsp60 ( Q321E position ) to stabilize
the hsp60/hsp10 mitochondrial complex in ATP conformation. Finally, they got the X-ray
structure of the hsp60/10 mitochondrial complex in ATP conformation (Figure 1.3).[53]
However, by comparing to the hsp60/10 wildtype chaperonin, this hsp60/10 mutant
chaperonin complex has no protein folding biological activities.

Figure 1.3. Crystal structure of the mtHsp60/mHsp10 American football complex with two
mHsp10 bound to both end of the mtHsp60 cylinder;
A. Side view of the football complex and their respective dimensions, seven subunits were
labeled with seven different colors. B. Top views from the north and south pole of the football
complex[53]
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1.2.2.2 Mitochondrial Hsp60 in Neuroprotection
Scientists have strong interest in the hsp60 chaperonin study of the protection of
the central nervous system, especially in the context of neurodegenerative disease and
other cellular insults that cause neuronal death. Many experimental evidences reveal
ways in which hsp60 chaperonin is a class of neuroprotective chaperonin.[54] When the
rat brain stem is induced by exposure to the pesticide, hsp60 chaperonin exerted its
neuroprotective effects by inhibiting the mitochondrial apoptotic cascade to rescue the
pesticide exposure condition.[55] Following pesticide exposure, hsp60 chaperonin
expression level was significantly increased, and it formed complexes with
mitochondrial and cytosolic Bax and mitochondrial Bcl-2, while dissociating from
cytosolic Bcl-2, therefore blocking pro-apoptotic signaling.[56] When the hsp60
chaperonin ceases to function by using antisense oligonucleotides or anti-hsp60
antiserum to silence , cell apoptosis increased [57].
Research on the neuroprotective mechanisms of Parkinson’s disease found that
L-DOPA administration was associated with increased expression of chaperon hsp70
as well as mitochondrial hsp60.[58] What is more, overexpression of the HSPs protein
was associated with higher expression and activity of complex I of the mitochondrial
respiratory chain. Increased hsp60 protein in the mitochondrion is an early protective
mechanism against neuronal damage caused by reactive oxygen and nitrogen species,
known contributors to side-effects that limit the long-term effectiveness of L-DOPA
treatment in Parkinson’s patients.[59] For the Alzheimer’s disease, overexpression of
hsp60 chaperonin protected complex IV of the respiratory chain against β-amyloid
stress and reduced the production of ROS, thus limiting apoptosis[60].
1.2.2.3 Mitochondrial Hsp60 Mutations and Neurological Disease
Four different mitochondrial hsp60 chaperonin mutations (D29G, Q461E, V98I
and V72I) have been found in several inherited families with neurodegenerative
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diseases.[61] The mitochondrial hsp60 Q461E polymorphism was identified in a
hereditary spastic paraplegia patient in a Danish cohort. E. coli expressing this
polymorphism showed impaired growth across a variety of temperatures compared to
wild-type Hsp60 (Hsp60WT).[62] The Hsp60 D29G mutation causes mitCHAP-60
disease, an autosomal recessive disorder involving brain hypomyelination and
leukodystrophy.[63] Both Hsp60 V98I and Hsp60 V72I mutations have been linked to
autosomal dominant hereditary spastic paraplegia type SPG13 [64-66]. E. coli
transfected with plasmids which can express that the Hsp60 V98I mutation chaperonin
had impaired mitochondrial protein folding capacity, reduced ATPase activity, and
limited cell growth across a range of temperatures by comparing to those expressing
hsp60 wildtype [65]. A similar growth impairment was seen by using the hsp60 V72I
mutation in the same E. coli system.[64] In addition to the alleged disease-causing
hsp60 mutations described above, there are some evidence that hsp60 polymorphism
might act as a genetic modifier, lowering the age of onset of disease in patients
harboring spastin mutation[67].
Neurodegenerative disease is a range of conditions that will lead to the
progressive loss of structure or function of neurons (the building blocks of the nervous
system, the brain and spinal cord), including death of neurons in the human brain.[68]
The neurons cannot be replaced themselves even if they are in damaged condition
without any reproduction and renewal, which may lead to some serve
neurodegenerative disorders, such as Parkinson’s, Alzheimer’s, Huntington’s and
amyotrophic lateral sclerosis et al.[69] Neurodegenerative diseases are devastating and
irredeemable conditions that result in progressive degeneration and / or death of nerve
cells. The symptom of the neurodegenerative diseases are problems with movement
(ataxias), or decreased ability to think and remember (dementias). Unfortunately, there
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are no effective treatment to cure the neurodegenerative diseases. What is more, the
detailed mechanism of the neurodegenerative disease still needs further investigation
and more efforts. However, it still shows that there are some similarities among the
neurodegenerative diseases. By investigating these similarities, scientists may get
some clues for therapeutic advances that could ameliorate many neurological diseases
simultaneously.

1.3 Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) is one type of inherited neurodegenerative
diseases with the progressive gait disorder feature. [70] The symptoms of this type
disease are showing with progressive stiffness (spasticity) and contraction in the lower
limbs, which are the result of dysfunction of long axons in the motor and sensory
systems in the spinal cord. [71]

1.3.1 The study history and classification of hereditary spastic paraplegia (HSP)
The study of the hereditary spastic paraplegia has long history, more than 100
years. Back to the year of 1876, hereditary spastic paraplegia (HSP) was first
introduced by a German neurologist named Adolph Seeligmüller by describing four
affected children with this disease.[72] After that, more hereditary spastic paraplegia
cases were studied extensively in 1888 by Maurice Lorrain[73], a French physician. The
disease is still named Strümpell-Lorrain disease in some French speaking countries to
memorial their contribution to study the disease. The well-recognized term hereditary
spastic paraplegia was first invented by Anita Elizabeth Harding , an Irish-British
neurologist, in 1983.[74] However, even after a lot of studies, the detailed mechanism of
this disease is still not well known.
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Because of the primary motor neurons are affected, the hereditary spastic
paraplegia (HSP) is an upper motor neuron disease [71]. HSP disease is caused by
defects in the transportation of proteins, such as structural proteins, cell maintaining
proteins, lipids, and other substances in the cell. Long nerve processes (axons) are
affected because long distances make nerve cells particularly sensitive to defects in
these mentioned mechanisms. [75]. Even though it physically appears and behaves
similarly to the spastic diplegia, HSP is not a group of cerebral, for the different
origin.[76] Even though knowing about that, the medication for the HSP disease is far
away for the treatment.
There are many classification criteria for the hereditary spastic paraplegia. In the
past, based on the patient's age at the onset of symptoms and on the amount of
spasticity versus weakness, HSP disease was usually classified as either type I HSP or
type II HSP.[77] Since both type I HSP and type II HSP can appear in the same
community ,besides that the age of onset has no clear relation to the genotype,
researchers try to use the other classification terms to validate the HSP disease more
accurate. Based on the mode of inheritance and genetic linkage, HSP disease can be
classified into several groups: autosomal dominant HSP type, autosomal recessive HSP
type, or X-linked, following the location of the gene, each type has several subtypes.[78]
Since symptoms of each type vary differently, the mode of inheritance cannot be used
to predict the severity of the inherit disorder. To date, the locations of several genes
associated with HSP disease have been identified. Eighteen types of dominantly
inherited pure or complicated HSP are known, along with 17 types of recessively
inherited HSP and 3 types of X-linked HSP.[71]
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1.3.2 The inheritance of hereditary spastic paraplegia (HSP)
HSP disease is a group of genetic disorders, following general inheritance rules
it can be inherited in an autosomal dominant, autosomal recessive or X-linked recessive
manner. The mode of inheritance involved has a direct effect on the chances of
inheriting the hereditary spastic paraplegia. Over 70 genotypes of the HSP diseases
had been defined, and more than 50 genetic loci have been linked to the HSP
diseases.[79] Among them, ten genes have been recognized in autosomal dominant
inheritance HSP diseases. Hereditary spastic paraplegia SPG4 disease is one type of
HSP disease, accounts for ~50% of all genetically solved cases, or approximately 25%
of all HSP cases. [80] Twelve genes have been identified to be inherited in an
autosomal recessive mode.[81] Collectively this latter group account for ~1/3 cases.
Most altered genes related to the HSP disease have been recognized their function, but
for some the function of the altered genes have not been identified yet. All of them are
summarized in the gene list (Appendix 1), including their mode of inheritance. Some
examples of the HSP diseases are spastin (SPG4) and paraplegin (SPG7), which are
both AAA ATPases.[82] Back in 2002 and 2007, researchers found that two mutations
(V72I , D3G)on the gene encoded for mitochondrial chaperonin hsp60 are related to
spastic paraplegia. It is been reported that purified mutant proteins exhibit reduced
ATPase activities and compromised ability to promote the folding of substrate proteins
in vitro. Moreover, E. coli complementation experiments revealed that expression of
hsp60 mutations inside the cells impaired the normal growth of the E. coli cells. Gain of
function study of gene microarray analysis also provided evidence that bacterial cells
holding hsp60 gene overexpression plasmid will upregulate the essential genes for the
E. coli cells growth. Given the essential role of the mitochondrial chaperonin hsp60 in
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mitochondrial protein folding activity, we can draw the conclusion that the dysfunction of
the mitochondrial hsp60 chaperonin by gene point mutation may result in the
neurodegenerative diseases. However, the detailed mechanism of the
neurodegenerative disease to understand the pathology is still unknown. Since Nterminal ends of long axons on these motoneurons are more vulnerable to ATP
shortages caused by malfunction of mitochondria or ATP synthase on the inner
membrane of the mitochondria, the dysfunctional mitochondrial hsp60 chaperonin
proteins typically have greater influence on the motoneurons in the lower limbs.[83] In
other words, mitochondrial chaperonin hsp60 plays a vital role in meditating the folding
activity.
Hereditary spastic paraplegia refers to a group of neurodegenerative diseases
characterized by weakness and spasticity (rigidity) in the lower limbs, which then slowly
progresses. These patients ultimately develop problems walking require a cane or a
wheelchair. What is worse, patients who suffered with advanced hereditary spastic
paraplegia also have additional symptoms including impaired vision, deafness, cognitive
impairment and others. All these conditions arise because of degradation of longest
axons in the motor and sensory systems in the spinal cord. To date, 72 spastic gait
disease-loci and 55 spastic paraplegia genes (SPG) have been identified in humans.
Mutations in these 15 genes result in malfunctioning gene products and defective
cellular processes.

1.3.3 The symptoms, mechanism, and treatment of Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) is a group of inherited disorders whose major
character is progressive weakness and spasticity (stiffness) of the legs.[70] Early stage
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of the hereditary spastic paraplegia may be mild gait difficulties and stiffness.[84] These
symptoms of the disease typically slowly progress , and eventually individuals with HSP
disease may require the assistance of a cane, walker, or wheelchair. Even though the
primary features of HSP disease are progressive lower limb spasticity and weakness,
complicated forms may be also accompanied by other serious symptoms. These
additional symptoms include impaired vision, ataxia (lack of muscle coordination),
epilepsy, cognitive impairment, peripheral neuropathy, and deafness.[85] The diagnosis
of HSP disease is mainly by neurological examination . Brain MRI is the most used
neurological examination methods to detect the complicated forms of HSP. Several
genetic mutations have been identified which involved in the HSP disease by
specialized genetic DNA sequencing and diagnosis. Not all people in a hereditary family
will inevitably develop the HSP disease, although they may be the dysfunction gene
carriers.[86] HSP symptoms can appear in either childhood or adulthood, depending on
the HSP related gene .[87]
There are various prognosis methods based on the severity of patients who
suffered with HSP symptoms. Some individuals are very disabled, while others have
only mild disability. Most individuals with uncomplicated HSP disease have the same life
expectancy as normal people.[88] Even though there are no specific treatments to
prevent, slow, or reverse HSP disease, symptomatic treatments can be used for
spasticity, such as muscle relaxants.[89] Regular physical therapy is also used for
muscle strength and to preserve range of motion.[90]
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The mechanism of Hereditary Spastic Paraplegia (HSP) is still not well known.
The symptoms are a result of the dysfunction of long axons in the spinal cord.[91] The
ends of the longest fibers, which supply the lower extremities, are affected to the
fibers.[92] Therefore, HSP is an upper motor neuron disease[71]. HSP causes
degeneration of the ends of the corticospinal tracts within the spinal cord. Even though
most HSP patients do not have symptoms in the hands or arms, some degeneration of
the fibers supplying the arms commonly take place.[93]
HSP may physically appear and behave the same as spastic diplegia, but it is not
a form of cerebral palsy because of the origin of HSP disease is different from cerebral
palsy.[94] Since HSP physically behaves like spastic diplegia, several of the same antispasticity medications used in spastic cerebral palsy are also used to release HSP
symptoms.[95] Many symptoms that are common in patients who suffered with HSP are
caused indirectly by muscle spasticity, weakness, or hyperactive reflexes.[89] Even
though there are no effective treatments for the HSP disease, some anti-spastic drugs
can be used to release or reduce the HSP disease.[89] Baclofen is widely used as a
skeletal muscle relaxant and a central nervous system depressant to induce the
hyperpolarization of afferent terminals and to inhibit monosynaptic and polysynaptic
reflexes at the spinal level.[96] Tizanidine is a centrally acting α2 adrenergic agonist
used as a muscle relaxant that is metabolized in the liver and excreted in urine and
feces to treat the spasms, cramping, and tightness of muscles caused by HSP
disease.[70, 97] Dantrolene is a postsynaptic muscle relaxant that stimulates muscle
relaxation by modulating skeletal muscle contractions at the site beyond the myoneural
junction and acting directly on the muscle itself.[98] Botulinum toxin (BTX) or Botox is a
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neurotoxic protein that binds to receptor sites on motor nerve terminals and inhibits the
release of acetylcholine, which in turn inhibits the transmission of impulse in
neuromuscular tissue.[99] Botulinum toxin can cause flaccid paralysis by preventing the
release of the neurotransmitter acetylcholine from axon endings at the neuromuscular
junction.[100] Anxiolytics and Benzodiazepines agents can be also used to induce
muscle relaxation by acting in the spinal cord.[101] Diazepam (Valium) is commonly
used to treat a range of conditions in all levels of the central nervous system by
increasing the activity of Gamma-Aminobutyric acid (GABA). [102] Even though these
agents can be used to release the HSP symptoms, they cannot cure the HSP disease
effectively. Also, there are lots of side effects caused by using those agents. One of the
drawbacks is that when patients are medicated to reduce stiffness, walking may
become more difficult.[103] Overall, the medicine for this disease is far away from
having a cure. Besides the medication treatment, the physical therapy can be also used
to release the HSP symptom.[104] Strengthening, stretching, and aerobic exercises can
be used as the regular Physical Therapy (PT) to maintain and improve Range of Motion
(ROM) and muscle strength, as well as to maintain aerobic conditioning of the
cardiovascular system to release the HSP symptom.[105] Although PT does not reduce
the degenerative process within the spinal cord and cure the HSP disease, it can help
the patient to improve muscle strength, minimize atrophy of the muscles, increase
endurance, reduce fatigue, prevent spasms and cramps.[106] Exercise also has a
positive psychological effect, helping the patient who suffered with HSP disease to
reduce stress.
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1.3.4 Mitochondrial hsp60 chaperonin and neurological disorder
The protein-folding machinery in the human mitochondria consists of a human
mitochondrial heat shock protein (hsp60) and its co-chaperonin, human mitochondrial
heat shock protein 10 (hsp10). They (hsp60/10 hereon) predominantly fold proteins in
the mitochondrial matrix but have also been found in extra-mitochondrial locations [13,
14] Misfolded proteins are associated with many well-known human diseases such as
Alzheimer’s disease, Parkinson’s disease, cancer, cystic fibrosis, and other
neuropathies, highlighting the importance of protein folding in human health [107-109].
Protein folding is an important cellular process that depends on proteins reaching their
native and fully functional three-dimensional structure. Cells have evolved
macromolecular machines called chaperonins that specialize in maintaining cellular
homeostasis by assisting proteins that have become misfolded. Protection provided by
chaperonins is critical to support life since deletion of chaperonin genes from bacteria
and yeast prove lethal [110-112]. Our studies focus on two neurodegenerative disorders
termed SPG13 and MitCHAP-60 that have been linked to mutations in the human
chaperonin hsp60. Although both disorders are neurodegenerative, they differ in the
clinical symptoms presented and mode of inheritance.
SPG13 is a member of Hereditary Spastic Paraplegia (HSP) group of
neurodegenerative diseases that are characterized by progressive weakness and
spasticity (rigidity) in the lower extremities [113, 114]. Patients with advanced HSP
diseases show additional symptoms including impaired vision, deafness, and cognitive
impairment. HSP diseases are neuropathologically characterized by degradation of the
longest axons in the motor and sensory systems in the spinal cord. To date, 72 spastic
gait disease-loci and 55 Spastic Paraplegia genes (SPG) have been identified in
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humans [114]. Our study focuses on the HSP disease SPG13, which is a dominantly
inherited form that presents at any age and is characterized by gait disturbances owing
to progressive spasticity and weakness of the lower limbs.
MitCHAP-60 is an early-onset neurodegenerative disease inherited in an
autosomal-recessive pattern characterized by neuronal hypomyelination and
leukodystrophy (brain white matter degradation) [115]. Patients show symptoms of
nystagmus (involuntary eye movement) and psychomotor developmental delays during
the first months of life that later progress to muscle weakness and limb spasticity
(rigidity). MitCHAP-60 usually leads to death within the first two decades of life [115].
Both SPG13 and MitCHAP-60 have been linked to point mutations in the heat shock
protein 60 (hsp60). A D3G hsp60 mutation is a missense mutation that has been linked
to MitCHAP-60 while a V72I mutation results in SPG13 [115-118]. Previous studies
have demonstrated that the disease-causing D3G and V72I mutations reduce the
chaperonin ATP hydrolysis activity and subsequently the protein folding ability of the
resultant hsp60 complexes both in-vitro and in-vivo [116, 118]. In this study, we
investigated the molecular mechanism by which the hsp60 mutations lead to the
MitCHAP-60 and SPG13.
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Chapter 2: Materials and Methods
2.1 The introduction of protein structural determination methods
Understanding how protein complexes accomplish their complicated function invivo is a central topic in molecular biology. Structural biology is a branch of the
biochemistry sciences that combines several disciplines, such as biology, physics, and
chemistry, to define in molecular terms the structures, mechanisms, and chemical
processes during the life-sustaining metabolism. The target of structural biology is to try
to understand how protein complexes function in-vivo by determining the 3D arrangement
of their atoms. X-ray crystallography, Cryo-EM and Nuclear Magnetic Resonance (NMR)
are the most common used techniques to determine macromolecular complex
structures.[119] Each structure determination method has advantages as well as
limitations. X-ray crystallography technique can generate atomic resolution with no
limitation of the complex size. However, the macromolecular complex should be
crystallized to get the structure which is sometimes impossible for the macromolecular
complex. Nuclear Magnetic Resonance (NMR) is also a useful tool to generate the
dynamic information of the small complex with Molecular Weights (MWs) below 40-50
KDa without the crystallization.[120] It is almost impossible to generate the structural
details of the macromolecular complex larger than 100 KDa. Another limitation of these
two methods that they typically require large amounts of relatively pure sample. For many
years, the determination of protein structure by cryo-electron microscopy (cryo-EM) was
limited to large complexes or low-resolution models. With recent advances in electron
detection methods and image processing software, the resolution by using cryo-EM is
now beginning to rival X-ray crystallography with fewer restrictions on sample size, and
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without requiring crystallization. Table.1 lists the comparison of the three macromolecular
complex structure determination methods.

Table.1: The comparison of the three macromolecular complex structure determination methods
Advantages

Disadvantages

Resolution

X-ray

1.Well developed

1.Need pure protein

High

Crystallography

2.High resolution

2.Need crystallization

3.No limitation for

3.Difficult for

the molecular weight

diffraction

1. High resolution

1. High sample purity

2.Dynamic 3D

2. Difficult sample

structure

preparation

NMR

High

3. MWs below 40-50
kDa
Cryo-EM

1.Easy sample

1. Costive for the

preparation

Cryo-EM

2.Purity is not problem

2. Need specialists to
collect data
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High

2.2 The introduction of Electron Microscopy (EM)

A microscope is an instrument used to investigate the small objects which are
beyond the human naked eyes.[121] The development of the microscope has a long
history. Numerous talented scientists brought the advent of the microscope to the public
and made it possible for the higher and better biological imaging resolution.
Microscopes can be categorized into many types based on different ways. Based on the
energy source usage, a beam of light or electrons, microscopy can be divided into
optical microscope, which uses visible light to pass through the object to generate an
image, and electron microscopy which uses electrons instead of light as the source of
illumination.[122]
Optical microscope, which is also called light microscope because of using the
light as the energy source, has the long history. The design of basic optical microscopes
is relatively simple, with sharing the basic components of the light path, such as ocular
lens, objective turret, objective lenses, focus knobs, stage, light source, diaphragm and
condenser, mechanical stage et al. [123]Based on using as single lens for magnification
or several lenses to enhance the magnification, the optical microscopy can be classified
into simple microscope and compound microscope.[124] In order to achieve the better
and higher resolution, researchers preferred the compound microscope as the most
used microscope in the contemporary research. Typically, photosensitive cameras can
be used to capture the images, such as traditional photographic film, charge-coupled
device (CCD).[125] Because of numerous advantages, optical microscope is the most
used microscope in both academia and industry. Comparing to other types
microscopes, optical microscope is affordable and portable, allows researchers to
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observe living organisms, such as bacterium, human cells, and even viruses. Optical
microscope uses the visible natural light as the energy source without any special aid
necessary and excessive components for the operation. Since the spectrum of light is
also cognizable to the human, the observation of the specimen is natural without any
artificial affected modification and damage. However, there are still lots of limitations on
the optical microscope. The wavelength of the light is the major boundary, which has
huge impact on the resolution. In terms of wavelengths, a typical human naked eye will
respond to wavelengths from about 390 to 700 nanometers.[126] Because of the
wavelength issue, there is an obvious boundary of an optical microscope to generate
adjacent structural details in high resolution. It is almost impossible to view the
specimens that are smaller than 0.275 microns or smaller than half the wavelength of
visible light by using the optical microscope. In addition to the wavelength, high
magnifications can also distort the image of point objects which may be surrounded by
diffraction rings.[127] What is worse, optical microscopy have limitations in the low
contrast uncolored biological specimens. Adding staining buffer can easily fix the
contrast problem, while makes the live biological specimens dead which may lose some
biological activities.
The development of the electron microscope with the first demonstration of the
principles by the physicist Ernst Ruska who won the Nobel Prize in Physics in 1986 and
the electrical engineer Max Knoll in 1931 to figure out the barrier of reaching higher
resolution, to achieve atomic resolution.[128] More scientists are joined to make
contribution to develop the powerful electron microscope afterward. As technology
progressed, developments on all the components, such as better vacuum systems,
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powerful electron guns, of the electron microscope made a big contribution to reach the
better resolving capabilities of electron microscopes. The major working principle of an
electron microscope is using a beam of accelerated electrons instead of light as a
source of illumination to generate the image of the object.[129] The wavelength of an
electron is around 100,000 times shorter than the visible light photos. Due to the
character of the wavelength, electron microscopes can determine the structure of
smaller objects in higher and better resolution. Without the invention of the electron
microscope, we cannot get such a huge achievement in almost all the natural science,
especially biological science. With the development of electron microscope, we can
achieve the atomic resolution of a wide range of biological and inorganic specimens
including the detailed architecture of the cell and the organelles as well as the structure
of viruses which are beyond the limitation of detection of the traditional optical
microscope. However, there are still many disadvantages and limitations of the electron
microscope. For the electron microscope, the main disadvantage is the price. It costs
more money than the traditional optical microscope. Besides, the huge size, extremely
sensitive maintenance, researcher training, and specimen preparation are also the
limitations. Unlike optical microscope, electron microscope cannot observe the live
specimen. Due to the penetration power of electron beam is relatively low, the specimen
should be cut into ultra-thin sections before the final observation. Figure 2.1 shows the
schematic diagram of a typical transmission electron microscope.
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Figure 2.1 Schematic diagram of a transmission electron microscope.
Adapted from a drawing provided by Roger C. Wagner, University of Delaware (Web site:
www.udel.edu/Biology/Wags/b617/b617.htm).

2.3 Cryo-EM

Cryogenic electron microscopy (Cryo-EM) is one type of electron microscopy
(EM) where the specimen must be cooled to cryogenic temperatures by using liquid
nitrogen or even liquid helium.[130] By far, the principal application of Cryo-EM to
biochemistry is concerned with visualizing biological complexity, such as protein
complex and virus complex, followed by interpretation of the image on a qualitative
descriptive level to understand the fundamental biological activities.[131] Since the first
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protein structure by using the three-dimensional Cryo-EM technology was deposited
with the Protein Data Bank (PDB) in 1997[132], the number of released protein
structures as well as the virus structures based on the Cryo-EM reconstruction has
increased exponentially. The invention of Cryo-EM made a huge contribution to the
structure determination of macromolecular complex, especially to the large, complex
and flexible structures such as membrane proteins, which are too difficult to be
crystallized for X-ray crystallography (XRD) or are too large for nuclear magnetic
resonance (NMR) spectroscopy.
Many talented researchers in the structural biology community have made
contributions to the evolution and revolution of cryo-EM in different ways for more than
eight decades. Without their dedicated work to the development of the technological
advancements including detectors, automation, software and specimen preparation, it is
almost impossible to achieve the advanced cryo-EM as well as the further application
for visualizing the structure. In 2017 Nobel Prize in Chemistry was awarded to three
outstanding researchers, Joachim Frank who developed the algorithms to analyze 2D
images and reconstruct them into the 3D structures, Jacques Dubochet who succeeded
in water vitrification to allow the specimen to stay the native state in the vacuum,
Richard Henderson who was first to utilize cryo-EM to achieve the 3D structure of
bacteriorhodopsin at atomic resolution.[133] With the aid of cryo-EM techniques,
researchers can now break the 3Å barrier to allow for high-resolution solving of difficult
crystallize macromolecular complex structures with large molecular weight that are
impossible by using the traditional techniques of XRD and NMR, along with an
unprecedented sharp rise in associated publications, which led to Nature Methods
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journal naming cryo-EM as its Method of the Year in 2015. [134]There are 230 EMDB
structures which solved by Cryo-EM which resolution is below 5 Å, among them there
are 18 EMDB structures with the resolution below 3 Å in less than five months of 2018.
Figure 2.2 shows Selected key events in the development of single-particle electron
microscopy (EM).

Figure 2.2 Cryo-EM timeline.
Selected key events in the development of single-particle electron microscopy (EM) are shown,
with milestones in techniques shown in the upper part and structures solved shown on the lower
part.[135]

Thanks to the outstanding work made by the talented researchers, cryo-EM is
becoming more and more portable. It starts with the vitrification process, in which the
protein solution is cooled too rapid to avoid the water molecules to form the crystals,
following by data collection using the cryo-EM to generate the particles in random
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distribution and orientations. The collected images are computationally extracted to
generate the two-dimensional class-averages. The reconstruction software is used to
process the 2D class-average to generate the accurate, detailed three-dimensional
biological structures at atomic resolution. The most common used reconstruction
software is RELION and Eman2.

2.4 Negative staining

The negative staining method is an easy, rapid, qualitative means for determining
the structure of the organelles, individual macromolecules and viruses at the EM level.
The negative staining method was first introduced by Brenner and Horne in 1959 to
obtain images of macromolecules for the high contrast. Negative staining method
utilizes heavy atom stains, typically 1 to 2% uranyl acetate to apply to the carbon-coated
sample grid for increasing the contrast between the specimen and its background.[136]
The heavy metal ions will replace the water molecules that hydrate the protein and
protect it from the radiation and vacuum damaging effects, causing the observed image
is of the dried “cast” instead of the real specimen [137]. Besides the distortion of the
molecule shape caused by air-drying process, negative staining has been achieved
great success in the large regular macromolecular reconstructions and virus
reconstructions which utilize symmetries to be avoided affecting by the distortion. Due
to high-contrast micrographs, longevity of the sample for re-imaging, minimal grid
preparation time, even in the cryo-EM era, the negative staining methods is still broadly
used in high-resolution EM of macromolecules as the initial stage in identifying
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characteristic sights, initial model for the further cryo-EM reconstruction. Figure 2.3a
shows the processing of the negative staining.

Figure 2.3 Negative stain and cryo-EM sample preparation[138].
(a) Schematic view of sample deposition, staining, and drying, with an example negative stain
image. (b) Schematic of plunge freezing and of a vitrified layer, and an example cryo-EM image.

Comparing to the cryo-EM reconstruction, the major limitation of the negative
stain-EM reconstruction is relatively lower resolution around 20 Å [139, 140]. However,
with the recent advances in both data collection and image processing methods,
negative stain-EM reconstructions have reached substantially higher-resolutions with
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recent reported 11.5 Å membrane protein resolution [141]. Negative staining images
always has higher contrast than the cryo-EM images which makes it easier to select the
particles (Figure 2.4 shows the comparison of Cryo-EM images with low contrast and
Negative images with high contrast). Researchers use the negative stain images to
build the model which can use for the cryo-EM processing as the initial reference. Also,
compare to cryo-EM, Negative staining processing is easier to handle.

Figure 2.4 The comparison of Cryo-EM images and Negative Staining images
A) Cryo-EM micrograph of the human mitochondrial hsp60 in APO conformation with low
contrast. B) Negative stain-EM micrograph of the human mitochondrial hsp60 in APO
conformation with high contrast.

2.5 Expression and Purification of Recombinant hsp60 and relative proteins
The bacterial expression and high-resolution purification of fully assembled
recombinant hsp60, hsp60 V72I mutant chaperonin, hsp60 D3G mutant protein, and cochaperonin hsp10 proteins will be presented in this section. Successful bacterial
expression of fully assembled and functional hsp60/10 chaperonin complex is likely due
to the evolutionary relationship and similarity of mitochondria to bacteria.[142] Hsp60
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forms a stable tetradecameric double-ring conformation in the absence of cochaperonin and nucleotide. Evidence of the stable double-ring conformation is
illustrated by the negative stain electron microscopy reconstruction presented here.
Although Hsp60 has been previously expressed in bacteria [143], the reported protein
was in a dynamic equilibrium between double and single ring conformations. Our
bacterial purification yields mostly the tetradecameric conformation of hsp60 with very
few monomers or single-ring conformations. Thus, our technique serves as a reliable
method for the large-scale production of homogenous hsp60 and hsp10 recombinant
proteins.
2.5.1 Cloning
The genes encoding the full-length wild type hsp60 (HspD1) and Hsp10 (HspE1) with
the mitochondrial targeting sequence were cloned into the pET-30a expression vector
system (EMD Millipore). Mature wild type hsp60 and the D3G and V72I mutations were
cloned into pET-22b plasmid. We designate the mutations as D3G and V72I since that
is the position in which they appear in the mature hsp60 protein that lacks the
mitochondrial signaling peptide. All the primers were synthesized by IDT company. All
the constructs were sequence verified by the Genomic Analysis Core Facility at the
University of Texas at El Paso. The following primers were used for cloning and
mutagenesis:
HspD1 Forward: 5’-GGAATTCCATATGAGGAGGTATGGCCAAAGATGTAAAATTTG
GTGC -3’ and Reverse: 5’-CCGCTCGAGTTAGAACATGCCACCTCCCATA-3’. HspE1
Forward: 5’-GTCGGGGCATATGGCAGGACAAGCGTTTAGAAAGTTTCTT -3’ and
Reverse: 5’-CCGGAATTCTCAGTCTACGTACTTTCCAAGAATGTCA-3’. HSPD1 D3G
mutagenesis: Forward: 5’-GCGCGCCATATGGCCAAAGTTGTAAAATTTGGTGCAGAT
GCCCG-3’ and Reverse: 5’-GGGGCTCGAGTTAGAACATGCCACCTCCCATAC CACC
-3’. HspD1 V72I mutagenesis: Forward: 5’-ACAAAAACATTGGAGCTAAACTTATT-3’
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and Reverse: 5’-TAAGTTTAGCTCCAATGTTTTTGT-3’. All the primers were
synthesized by IDT company. All the constructs were sequence verified by the Genomic
Analysis Core Facility at the University of Texas at El Paso. pET-26b vectors encoding
the human ATP synthase F1 subunit alpha (ATP5F1A) and human ATP synthase F1
subunit beta (ATP5F1B) were ordered from GenScript.
Table 2.1: hsp60 PCR component

component

50 µl REACTION

Final concentration

5X Q5 Reaction Buffer

10 µl

1X

10 mM dNTPs

1 µl

200 µM

10 µM Forward Primer

2.5 µl

0.5 µM

10 µM Reverse Primer

2.5 µl

0.5 µM

Template DNA

200ng

< 1,000 ng

Q5 High-Fidelity DNA

0.5 µl

0.02 U/µl

(10 µl)

(1X)

Polymerase
5X Q5 High GC Enhancer
(optional)
Nuclease-Free Water

to 50 µl
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Table 2.2: Thermocycling Conditions for hsp60 PCR

TEP

TEMP

TIME

Initial

98°C

30 seconds

98°C

10 seconds

72°C

30 seconds

72°C

30 seconds

72°C

2 minutes

Denaturation
35Cycles

Final
Extension
Hold

4–10°C

2.5.2 Protein expression and purification
Unless otherwise stated, all chemicals, antibiotics, and growth media were
purchased from Sigma-Aldrich. E. coli BL21 (DE3) cells were purchased from New
England Biolabs. Hsp60 and hsp10 were expressed and purified as described in
Enriquez et al 2017 [142]. Briefly, the proteins were expressed in E. coli BL21 (DE3)
cells cultured in 2xTY medium at 37 ℃. Cells were induced with IPTG at 30 ℃ for 4
hours and were subsequently harvested by centrifugation at 5000 x g for 30 minutes
and lysed in a buffer containing 50 mM HEPES pH 7.5, 50 mM EDTA, 0.02% NaN 3. The
cells were then lysed by treatment with hen egg white lysozyme and multiple
freeze/thaw cycles. The viscous lysate was treated with porcine liver DNase and 100
mM MgCl2 to degrade DNA. Crude lysates were then treated with saturated ammonium
sulfate to a final concentration of 50% (v/v) to precipitate the recombinant protein.
Recombinant hsp60 and hsp10 were subsequently purified independently using anionexchange and size-exclusion column chromatography (NGC Chromatography Systems,
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Bio-Rad) using chromatography buffer containing 50 mM HEPES, pH 7.5, 5 mM EDTA,
150 mM NaCl, and 0.02% NaN3.
The ATPase synthase subunits α and  were purified as described in Miwa and
Yoshida, 1989 [144]. The proteins were expressed in E. coli BL21 (DE3) cells cultured
in 2xTY medium at 37C and induced with IPTG for four hours at 30℃. Cells were spun
as described above, lysed, and crude lysates were purified with saturated ammonium
sulfate added to a final concentration of 75% (v/v). Proteins were purified by ionexchange and size-exclusion chromatography using chromatography buffer containing
50 mM HEPES buffer, pH 7.0, 5 mM EDTA, 200 mM Na 2SO4. SDS-PAGE and
bicinchoninic acid (BCA) protein assay were utilized to estimate sample homogeneity
and the concentrations of all purified proteins, respectively.

2.6 Negative stain electron microscopy for the mitochondrial hsp60 chaperonin
and its mutants

Purified chaperonin samples at a concentration of 0.2 mg/ml were applied to
continuous carbon film with 400-mesh copper grids that were previously glow
discharged for 30 seconds. Excess protein solution was wicked off with Whatman-1
filter paper and grids were stained with 2% methylamine tungstate and 2% uranyl
acetate. The negative stain imaging was performed using a JEOL 3200FS transmission
electron microscope operated at 300 kV and the images were collected between 0.3–
2.5 m under-focus and at a magnification of 138,000X using a Gatan UltraScan CCD
camera. The pixel size calculated for the data set was 1.09 Å/pixel.
Structure determination is a procedure by which the three-dimensional atomic
coordinates of a molecule or biomolecule complex are solved using an analytical
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technique. Here we will present how to use negative staining technique and structure
determination software to generate three-dimensional structure of mitochondrial hsp60
chaperonin and its mutants.

2.7 Particle Picking

After we got the EM images form the microscopy, the first step in the
computational pipeline of single-particle electron microscopy (EM) termed “particlepicking” that determine the central position (coordinates) of the particles in the images
and then subsequently merging the particles into a single computer file [145]. The
coordinates are identified by putting “boxes” around the particles with the center of the
box placed as closely to the center of the particles as possible to extract the whole
particle. As high-resolution reconstruction of the macromolecular complex typically
requires hundreds of thousands of particles, manually picking for that processing is a
time-consuming work.[146] The particle-picking process can be performed with the help
of auto-picking algorithms that significantly save the user time. Auto-picking has its
drawbacks as it requires manual template of the auto-picked particles. While semiautomated particle picking is currently a popular approach, it also has drawbacks by
introducing manual bias into the selection process.[147] Proper box size and particle
centering are the two important parameters in the particle picking processing for
generating high-resolution reconstructions of the macromolecular complex. [145]. Since
the high contrast in the negative staining micrographs, it is more readily observed in the
particle picking process and much easier to pick the particles than the cryo-EM images
because of the low contrast. Figure 2.4 shows the comparison of Cryo-EM images and
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Negative Staining images. Figure 2.4 A) shows the cryo-EM micrographs of human
mitochondrial hsp60 in APO conformation with low contrast while figure 2.4 B) shows
the negative stain-EM micrograph of the human mitochondrial hsp60 in APO
conformation with high contrast.
Here we use e2boxer software for the particle picking processing. The Figure
2.5 showed the e2boxer particle picking processing for the hsp60 V72I mutant APO
micrographs. The semi-automated particle picking methods is used to choose the good
particles over micrographs of different defocus range, and the particles are centered.
Then the good particles are used as the template for the auto particle picking. In some
software, such as RELION software, the two-dimensional model will be built by the
manual picked particles. Then the good two-dimensional class average will be chosen
as the template for the auto particle picking. In order to get good template, the
processing of 2D class average will run several times. In our project, we also run the 2D
class average processing several times.
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Figure 2.5 Particle picking of hsp60 V72I mutant chaperonin by using e2boxer software

2.8 Contrast Transfer Function (CTF) correction
The contrast transfer function (CTF) mathematically describes how aberrations
in a transmission electron microscopy (TEM) modify the micrographs of a sample in
Fourier space. Due to the imperfect imaging conditions in TEM, the observed particles
contain distortions caused by the aberrations that need to be corrected before highresolution single particle analysis.[148] The distortions are increased when the TEM is
defocused to impose contrast in the particles, as in cryo-EM, but the effects are
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contained in all TEM images and the corrections are a fundamental part of the 3-D EMreconstruction process.[149] The contrast transfer function (CTF) of the microscope is
the mathematical representation of the contrast inducing events.[136] Comparing to the
ideal images, the main degrading effects of the under-focus CTF on the image can be
describe as a combined low-pass and high pass filtration. The CTF is a sinusoidal
function that varies with defocus and spatial frequency (resolution).[150] The resolution
of the images is limited by the aperture function. Due to the increasingly rapid
oscillations of the CTF, it is very difficult to exploit the images information. Ideally, the
information is transferred out to high spatial frequencies in the absence of aperture.
However, the illumination has finite source size and finite energy spread. If we go
toward higher spatial frequencies, the partial coherence dampens the CTF and
ultimately limits the resolution.
Without CTF correction the desired 3-D reconstruction will contain imaging
artifacts that ultimately limit the obtainable resolution for the reconstruction [136]. Some
software is developed to do the CTF correction, the most common used are the GCTF
and CTFFIND 4. To make CTF conforms more closely with the ideal behaviors,
researchers made numerous attempts, such as changing the wave aberration function
through intervention in the back focal plane, designing zone plates to block out the
waves may have destructive interference for a particular defocus setting.

40

Fig.2.6 The influence of different Defocus Value on the Contrast Transfer Function
(CTF).
(figure from https://spider.wadsworth.org/spider_doc/spider/docs/techs/ctf/ctf.html.)

2.9 Sorting and 2-D Class Averaging of Picked-Particles

The next step in the reconstruction process is to classify the orientations of the CTF
corrected particles in relation to one another. 2-D class averaging is initially understood
as an operation that is performed on two or more images with the aim of bringing a
homogeneity contained in those images into register. The introduction of heterogeneous
image set need to generalize the term alignment to minimize a given functional. There
are several obstacles should be faced in the 2-D class averaging of picked-particles,
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such as lacking clarity and definition images, limited resolution, fidelity to the objective
by instrument distortions. In a word, all the problem arises from the fact that EMmicrographs are inherently noisy resulting in a low signal to noise ratio (SNR) for the
observed particles [151]. To increase the SNR numerous particles are averaged
together to boost the signal resulting in a particle with more discernable features [152].
To further complicate matters, the 2-D particles assume random orientations on the EMgrid that need to be sorted and placed into classes based on their correlation to each
other [145, 153]. The single particle reconstruction methodology is completely
dependent on the power of averaging and requires that large numbers of particles be
obtained; in some cases hundreds of thousands to millions of particles are required for
high-resolution structures [151, 154]. For that case, powerful computers or computer
clusters are required for the processing of these large image data sets and even optimal
averaging can be a computationally expensive process. The high-contrast of negative
stain particles gives a higher SNR than cryo-EM and results in the need for smaller
particle sets to increase the SNR to otain accurate particle classification.
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Figure 2.7 Reference-free 2D class average of hsp60 V72I mutant chaperonin

The reference-free 2D class average will categorize particles based on the
different orientations or conformations into different groups. Because of this, bias
induced by 3D structure can be avoided and structural details can also be preserved.

2.10 Reconstruction of an Initial 3-D Structure from 2-D averages

Once 2-D class averages have been generated, the bad class averages should
be removed for the further processing. The 2-D class averages which are structural
heterogeneity should be selected to combine them to reconstruct the original 3-D
molecule. The projection slice theorem interprets the 2-D particles as projections of the
starting 3-D initial model [153]. The theorem states that the Fourier-transform of the 2-D
particle represents a central slice through the volume of the 3-D molecule in Fourierspace [153]. The combination of these central slices over a large angular range enables
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the reconstruction of the 3-D molecule in Fourier space [154]. The inverse Fouriertransform brings the reconstructed Fourier 3-D volume back into real space rendering
the 3-D structure of the original molecule [154].
The 3-D reconstruction initially generated (initial model) is usually relatively low
resolution due to the inaccurate placement of particles in their respective classes upon
initial sorting and inadequate processing rounds. The inaccuracy of the structural
projection arises from the de-novo building of the class averages that is referred to as
reference-free class averaging [155]. The lack of a reference ensures that bias from
another model is not introduced into the initial model and subsequently unaffected the
final 3-D reconstruction. Reference based particle picking and class averaging is a very
powerful and time-saving technique; however, it can lead to biasing of the data since it
only picks particles that match the reference and leaves out any novel conformations of
the protein that mismatch the reference [145]. Class averaging has multiple advantages;
it not only allows for the sorting of particles but also results in the enhancement of the
constant features of the particles and subsequently a substantial reduction noise [151].
Reference-free class averaging was used for all the presented negative stain-EM
reconstructions of the human mitochondrial chaperonin in the subsequent chapters.

44

Figure 2.8 The initial model of hsp60 V72I mutant generated by Eman2 software

2.11 Iterative Refinement of a 3-D Reconstruction and Resolution Determination

The refinement of 3-D reconstructions is an iterative process and can take
numerous rounds to properly classify the particles and generate a structural model in
high resolution level [156]. The initial model is used to generate a set of 2-D projections
over a sufficient angular range that act as references for re-classification of the particleset [153]. The new classes are then utilized to reconstruct a second model that is better
in quality than the initial reference model. The convergence of the data is monitored
both visually and through analysis of the Fourier shell correlation curve (FSC) [157].
The FSC is a function that when plotted versus resolution provides a means of
quality evaluation and resolution assessment [158]. The FSC is based on the computing
by randomly splitting the data in half and generating a reconstruction from each half-set;
in EMAN2 reconstruction software and the RELION reconstruction software, the halfsets are the even and odd numbered particles [145]. The correlation between the
Fourier transforms of the even and odd reconstructions is then measured as a function
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of resolution [159]. The FSC curve starts out at 1 for low resolutions and then sharply
declines towards 0 in a sigmoidal fashion [152]. This indicates that structural agreement
of the data at low resolutions is quite good while at higher (desired) resolutions the
correlation is generally poor [152]. There are two criterions that are generally accepted;
the 0.5 cut-off that is used for low resolution reconstructions and the 0.143 cut-off that is
generally for reconstructions higher than 10 Å in resolution [159]. In our study, since we
use the negative stain as the method to generate the protein reconstruction, the
resolution is relatively low by comparing to the cryo-EM methods, we use the 0.5 cut-off
instead of 0.143 cut-off to get the accurate resolution value.
When the final model reconstruction has been gained, the next movement is to
validate the final reconstruction. High-resolution reconstruction such as those model
higher than 5 Å in resolution will provide enough detail that they can have their C-α
protein backbone traced in Gorgon and SSEHunter software [145, 160, 161]. If there is
the X-ray crystal structure in the PDB (protein data bank), we can also use the X-ray
crystal structure as the mode for the fitting and further validation of the final EMreconstruction. Even though the fitting process is generally performed on high-resolution
structures, it can still provide valuable analysis on the structural features in lower
resolution cryo- and negative stain-reconstructions to get the general information [162].
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Figure 2.9 Schematic of single-particle reconstruction Protein purification [163].

Besides generate the initial model for the cryo-EM reconstruction, negative stain is
also useful to clearly visualize the sample and check the homogeneity of the
macromolecular complex, especially for small particles. Particles are boxed from the
micrographs, centered and aligned. [163]Classification and averaging can give
improved SNR, and class averages can be used to obtain a relatively low-resolution
initial model by common lines or tilt methods. Figure 2.9 shows the processing how to
generate the high-resolution structure form the EM images. In cryo-EM, the vitrified
sample is imaged by collecting movie frames that are aligned for motion correction and
then averaged (Figure 2.9). Defocus determination and CTF correction are done on
motion-corrected averaged images. [164]After alignment, classification and cleaning of
the dataset, particles are assigned orientations by projection matching to the initial
model which may generate by the negative stain reconstruction. Orientation refinement
is performed iteratively until the structure converges.
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2.12 ATPase activity assay

The ATPase activity assay was performed using the EnzChek Phosphatase
Assay Kit (Molecular Probes, Leiden, The Netherlands) which measures the inorganic
phosphate released from ATP hydrolysis during protein folding enzymatic reactions.
The substrate -lactalbumin was denatured with the addition of 0.5 mM EDTA and 50
mM DTT. The resultant mixture was heated to 98C for 5 minutes and allowed to cool
before a 10-minute incubation period with 200 M MESG, 0.2 units Purine Nucleoside
Phosphorylase (PNPase) and the kit reaction buffer. Next, 200 M ATP and 200 M
MgCl2 were added to a 100 L reaction followed by addition of 1 M hsp60 and 2 M
Hsp10. A continuous colorimetric measurement at 360 nm was initiated immediately
after the addition of hsp60 and Hsp10. 2-amino-6-mercapto-7-methylpurine has
maximum absorbance at 360nm, spectroscopy can be used to monitor the generation of
reaction product, the inorganic phosphate generated from the ATPase activity of
chaperonin protein mtHsp60 can be quantified.
Assays to refold the β subunit of the ATP synthase were performed as follows.
The purified  subunit was thermally denatured by incubating at 55℃ for 20 min [165]. A
reaction was set up with 200 M MESG, 0.2 U PNPase, 200 M ATP, 200 M MgCl2, 1
M hsp60, 2 M Hsp10, 1 M subunit α, and 1 M denatured subunit β. Next, the
reaction buffer was added to yield a final volume of 100 L. A continuous colorimetric
read at 360 nm was initiated to monitor the rate of ATP hydrolysis.
Human mtHsp60 protein requires hydrolysis of ATP to perform the chaperonin
protein folding cycle, resulting the release of inorganic phosphate and ADP molecule.
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By measuring the amount of the released inorganic phosphate, we can get the hsp60
protein folding activity. Purine nucleoside phosphorylase (PNPase) is an enzyme that
enzymatically converts a substrate 2-amino-6-mercapto-7-methylpurine riboside
(MESG) to ribose 1-phosphate and 2-amino-6-mercapto-7-methylpurine by reacting with
inorganic phosphate (Pi) (Figure 2.10). Maximum absorbance for the substrate MESG is
at 330nm whereas the maximum absorbance of the purine product is at 360nm. Upon
the ATPase activity of the chaperonin is present, the enzymatic conversion of MESG to
the purine product will be happened, resulting a spectrophotometric wavelength shift
from 330nm to 360nm. The rate at which absorbance at 360nm increases can be
related back to a calibrated amount of purine product through Beers’ Law. The
relationship between production of the purine product by PNPase to the ATP hydrolyzed
by the chaperonin ATPase activity is stoichiometric. There is exactly one purine product
produced for ATP molecule hydrolyzed.
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Figure 2.10 Reaction Scheme of conversion of substrate MESG to ribose 1-phosphate and
2-amino-6-mercapto-7-methylpurine by purine nucleoside phosphorylase by reacting with
inorganic phosphate which released by the chaperonin protein human mtHsp60

2.13 MDH refolding assay

Malate dehydrogenase (MDH; EC 1.1.1.37) is an NAD oxidoreductase that
catalyzes the NAD/NADH-dependent interconversion of malate and oxaloacetate. This
reaction is critical to maintain the malate/aspartate shuttle across the mitochondrial
membrane and Krebs tricarboxylic acid cycle in the mitochondrial matrix.[166] Increased
MDH activity has been observed in neurodegenerative diseases such as Alzheimer′s
disease. We used the malate dehydrogenase as the substrate to detect the protein
folding activity of the mitochondrial hsp60 chaperonin and its mutants.
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Malate dehydrogenase (MDH) at a concentration of 62.5 nM porcine was
denatured in 10mM HCl for 1 hour at room temperature and diluted 1:50 into a buffer
containing 0.1 M Tris-HCl pH 7.4, 7 mM KCl, 7 mM MgCl2, 10 mM DTT, along with 1.3
μM hsp60, 2.6 μM Hsp10, and 0.5 mM ATP. After 5 mins of incubation at 37°C, the
Malate Dehydrogenase Assay Kit (Sigma, MAK196) was used to measure the renatured
malate dehydrogenase activity. The MDH enzymatic activity was determined by
measuring the absorbance at 450 nm.

2.14 Dynamic light scattering (DLS)
All experiments were performed on a Malvern Zetasizer Nano ZS instrument. For
the ATP-bound conformation, 1 µM hsp60 (wild type or mutant) was added to 2 µM
hsp10, 100 mM ATP, and 100 mM MgCl2. For the ADP-bound conformation, 1 µM
hsp60 (wild type or mutant) was added to 2 µM hsp10, 2 mM ADP. The samples were
incubated for 5 minutes at 37°C upon addition of nucleotides. The excess unbound
nucleotides were removed with desalting spin columns (Thermo Scientific). All the data
are reported as percent volume to normalize the measurement with the amount of
protein at each size. 180 measurements were averaged together to give a statistically
significant size distribution that describes the hydrodynamic diameter of the complexes.

51

Chapter 3: Results
3.1 Protein purification results

Figure 3.1 Purified chaperonin, mutants, and substrates.
a) SDS-PAGE of all the expressed and purified recombinant proteins used in our studies. The
α and β subunits of the Human F1 ATP synthase appear to be the same size as the hsp60.
Hsp10 runs anomalously as a 12 kDa protein. b) A negative stain electron micrograph of hsp60
illustrating the formation of tetradecamers. The red arrow highlights a side-view of a
tetradecamer and the white arrow points to an end view.

Human heat shock proteins (wild type hsp60/10 & mutants) and human F 1 ATP
synthase subunits (α and β) were expressed in E. coli and each purified to near
homogeneity as described in the methods section. After each round of purification, the
purity of all the proteins was estimated by SDS page analysis and determined to be
near homogeneity (Figure 3.1). Negative stain electron microscopy was done on freshly
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purified wild type hsp60/10 protein without nucleotide to make sure complexes were
formed correctly (Figure 3.1b).

3.2 Negative staining results of mitochondrial hsp60 wildtype

Figure 3.2 Negative staining images of mitochondrial hsp60 wildtype chaperonin and
cochaperonin hsp10 in different Nucleotide conformation.
A) mitochondrial hsp60 in APO conformation (no nucleotides) B) mitochondrial hsp60 with
cochaperonin hsp10 in ATP conformation C) mitochondrial hsp60 with cochaperonin hsp10 in
ADP conformation

From the Figure 3.2, we can easily get the conclusion that mitochondrial hsp60
wildtype has different configurations during different stage of protein folding cycle. The
hsp60 APO is a tetradecamer complex that does not bind to the cochaperonin hsp10
without the nucleotides. The hsp60 chaperonin protein folding cycle is initiated by ATP
binding to one ring in the APO-hsp60 tetradecamer followed by cochaperonin hsp10
binding to form the bullet complex. Binding of ATP and hsp10 to the cis-ring is ready for
the trans-ring for acceptance of ATP and hsp10 to form the American football structure.
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Upon the hydrolysis of ATP, the football complex dissociates into two single ring
complexes. After the release of folded substrates and the cochaperonin hsp10, the two
single rings will transform into the tetradecamer complex again. The protein folding
cycle happens instantaneous.

3.3 Negative staining results of mitochondrial hsp60 mutants

Figure 3.3 EM Negative staining images of mitochondrial hsp60 V72I mutant chaperonin
were collected under three conditions.
A) APO; B) ATP; C) ADP. For ATP and ADP conformation (B and C), the mutant hsp60s fall apart
with nucleotide.

We also treat the hsp60 V72I and D3G mutant chaperonin for the same condition
that we used for the hsp60 wildtype chaperonin. Both the V72I hsp60 mutant and the
D3G hsp60 mutant still form the tetradecamer complex that behaves the same
characters as the hsp60 wildtype chaperonin. The two mutant hsp60 chaperonins also
do not bind the cochaperonin hsp10 without the nucleotide. For the nucleotide
conformation, 100 mM is used for both ATP and ADP conformation of the hsp60-V72I
mutation and hsp60-D3G mutation study which is more than 20 times than the
concertation in-vivo (2-10 mM). All the two mutations will fall apart into the monomer
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configuration in the nucleotide conformation, either ATP conformation or ADP
conformation. At the very beginning, we thought that higher concertation nucleotide
would be the reason for the mutation protein falling apart. However, we use the same
concertation nucleotide for the wild-type hsp60 as the control. Interestingly, for the ATP
conformation, the “bullet” and “America football” configuration was formed; for ADP
conformation, the single ring configuration was formed. (unpublished data) We also tried
normal nucleotide concertation (2 mM) for both wild-type and mutation, the protein
always stayed in double-ring configuration which is the same configuration as APO
conformation (without nucleotides). We do not know the exact mechanism that why the
hsp60 protein need much higher nucleotides in vitro than in-vivo. We assumed that the
higher nucleotides concertation is also needed, since the protein folding is fast step, the
nucleotides concertation is also high during the folding step which is difficult to capture.
The average nucleotide is normal. However, much research should do for this
hypothesis.

3.4 Hsp60 mutant structure determination

We collected data under the following conditions to capture the major nucleotidedependent conformations within the hsp60/10 protein folding cycle. For the ATP-bound
conformation (without hsp10), 2 mM ATP was added to hsp60. For the ATP-bound
conformations in the presence of hsp10, 100 mM ATP was added to Hsp60 and Hsp10
(2:1 molar ratio). To obtain the ADP conformation, 2 mM Mg-ADP was mixed with
hsp60 and hsp10 (1:1 molar ratio). The purified proteins with incubated with the
nucleotides at room temperature for approximately five minutes before they were
applied to the grids. A total of 583 particles were picked from the negative stained
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micrographs using EMAN2 [155]. CTF correction, reference-free class averaging, initial
model building, and single particle reconstruction were all performed in EMAN2 [145].
Visualization and figures were generated using UCSF’s Chimera [167].

Figure 3.4 The process of generating three-dimensional structure of mitochondrial hsp60
V72I mutant

Due to the heterogeneity in the hsp60/10 ATP-conformation dataset, a slightly
different approach was utilized to separate the particles corresponding to the bullet and
football complexes. The reference-free class averages that corresponded to the sideviews of the two complexes were separated and individually used to generate two low
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resolution initial models. The two models were then used as references for the EMAN2
version of multi-refine to separate the particles into two sub-sets. The total data-set
contained 3203 particles that were split into sub-sets containing 1654 (bullet) and 1536
(football) particles. Once the particles were split, single refinements were performed for
both data-sets. C7 symmetry was used for the bullet refinement due to the different
conformational states of the two rings. The bullet reconstruction converged to a
resolution of approximately 17 Å. D7 symmetry was used for the refinement of the
football complex that converged to approximately 20 Å. The football complex generated
in EMAN2 served as an initial model for additional refinements in RELION2 to reduce
the amount of noise in the 3-D reconstruction [155, 168]. For the hsp60 D3G and V72I
APO conformations, 3144 and 2491 particles were picked form the negative stained
micrographs, respectively. CTF correction, reference-free class averaging, initial model
building, and single particle reconstruction were all performed in EMAN2. D7 symmetry
was applied for the refinement using Eman2.
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Figure 3.5. Negative stain reconstruction of mutant hsp60.
a) The V72I mutant resulted in an APO reconstruction that has a square appearance when
viewed from the side. Upon the addition of nucleotide (either ATP or ADP), most of the
chaperonin complexes fell apart. Consequently, no reconstruction was possible. b) The D3G
mutant also resulted in an APO reconstruction but it had a more rounded appearance when
compared with the V72I mutant reconstruction. Just as with the V72I mutation, the addition of
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nucleotide caused most of the mutant chaperonin to fall apart. c) The inability to undergo
conformational changes upon nucleotide addition results in both mutant chaperonins to fall
apart.

3.5 Architecture of the wild type hsp60/10 complex in the absence of substrate

The wild type mitochondrial hsp60/10 chaperonin utilizes the energy derived
from ATP hydrolysis to undergo conformational changes that drive the protein-folding
reaction. In the absence of substrate, the chaperonin complex stalls and does not
progress along the protein-folding pathway until substrate is added. We exploited this
behavior to obtain near homogeneous conformations after the addition of nucleotide.
Negative-stain electron microscopy on purified wild type protein without the addition of
nucleotide resulted in double-rings that did not bind to hsp10 (Figure 1b and Figure 3a).
This was termed the APO conformation. Upon addition of 2mM ATP to the same
sample, the conformation changes to a double-ring structure with hsp10 bound to one of
the rings (“bullet” structure). Addition of a higher concentration of ATP (100mM) results
in a conformation that is shifted from hsp10 binding to only one ring to binding on both
rings (“American Football”). The addition of ADP mimics the ATP hydrolyzed state that
produces a conformational state that induces ring separation resulting in single-rings of
hsp60 with hsp10 bound. Negative-stain single-particle image processing resulted in
low resolution reconstructions that better illustrate the conformational states as dictated
by the nucleotide binding pocket.

The X-ray structure of a chimeric complex of the

mutant human mitochondrial Hsp60E321K with mouse mitochondrial Hsp10 (PDB 4PJ1)
was fit into the reconstructions for structural validation. No fitting of the single ring was
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performed because there is no X-ray structure of the single-ring. Based on the
reconstructions of different conformations, we postulate a likely protein-folding cycle
with the various intermediates along the catalytic pathway.

3.6 Architecture of the mutant hsp60/10 complexes
A similar approach as the wild type chaperonin was taken for the D3G and V72I
mutant complexes. Negative stain raw micrographs of the two mutants show that just
like the wild type chaperonin, each of the mutants can form double-ring complexes that
do not bind hsp10 in the absence of substrate and nucleotide (Figure 5a, APO
conformation). Addition of either ATP or ADP resulted in mutant chaperonin complexes
that fell apart (Figure 5C).
After the structure generated by the software, the dynamic light scattering (DLS)
bio-chemical techniques will be used to confirm the generated structure to avoid the
biased structure.[142] Dynamic light scattering (DLS) is a non-invasive technique to
determine the size distribution profile of small particles including proteins, polymers,
micelles, vesicles in suspension or polymers in solution.[169] The theory of the DLS is
light emitted from a laser source interacts with protein particles in solution that scatter
the incoming light. The fluctuations in the intensity of light indicate the determination of
a proteins size distribution in the solution.[169]

The size distribution of the protein (the

polydispersity index) indicates the degree of conformational heterogeneity of the protein
complex. DLS measurements can be used to characterize chaperonin complexes to
confirm with the cryo-EM structure [170]. In this section, DLS was used in this study to
determine the sizes of the various complexes formed by the human mitochondrial
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chaperonin hsp60 and its mutants in different Nucleotide conformations to study the
mechanism of the protein folding cycle. Negative-stain electron microscope data for low
resolution three-dimensional reconstructions was only obtained from the APO
conformation. A reconstruction of the mutants in the presence of nucleotide was not
possible due to the heterogeneity and low numbers of individual mutant chaperonin
complexes.

3.7 Dynamic light scatting (DLS) validation of structure reconstruction

To validate the negative-stain EM reconstructions, we performed dynamic light
scattering (DLS) experiments on the wild type and mutant complexes to determine if the
complexes were disassembling into monomers, Wild type hsp60/10 complexes
remained in a tetradecameric conformation when nucleotide was added (Figure 8 a).
The structure was slightly larger in the presence of ATP due to hsp10 binding at both
ends of the complex. The D3G and V72I mutants on the other hand reveal an abrupt
change in size upon the addition of nucleotide indicating a catastrophic event that led to
the disassembly of the complex into monomers (Figure 8 b & c). The tetradecameric
complex is about 16 nm in size while the monomer is expected to be about 9 nm based
on the X-ray structure of one hsp60 subunit
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Figure 3.6. Dynamic light scattering reveals mutant hsp60 disassembly.
a). Dynamic light scattering (DLS) analysis of the hsp60 wildtype conformations in absence
and presence of nucleotides. b). Dynamic light scattering (DLS) analysis of the hsp60 V72I
mutant conformations in absence and presence of nucleotides. c). Dynamic light scattering
(DLS) analysis of the hsp60 D3G conformations in absence and presence of nucleotides. Each
curve reveals a different hydrodynamic diameter of the hsp60 chaperonin in the ATP bound
(blue curve), ADP bound (cyan curve) and APO conformation (red curve).
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3.8 The ability of the mitochondrial hsp60 chaperonin to refold unspecific
denatured protein
We used the denatured α-lactalbumin as the substrate for the hsp60 chaperonin
protein folding activity. From figure 3.8, we can see the maximum absorbance of wildtype mtHsp60 is around 1.0 whereas D3G mutant is around 0.1, V72I mutant is around
0.2 indicating that D3G mutant and V72I mutant mtHsp60 only have 10-20% of ATPase
activity compared to hsp60 wild-type counterpart. We can get the conclusion that the
hsp60 wildtype which we used in our study still have the biological activity, while the
mutants had significantly diminished activity.

Figure 3.7 α-lactalbumin protein folding assay.
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ATPase activity of Recombinant Human Mitochondrial wild-type hsp60/hsp10 (yellow), V72I
mutant/hsp10 (red) and D3G mutant/hsp10 (blue) in the presence of denatured α-lactalbumin
substrate was measured by EnzChek Phosphate Assay. The assay measures released
inorganic phosphate (Pi) in the absorbance at 360 nm as a result of ATP hydrolysis by the
chaperonin. The phosphate assay is generated using the monosodium phosphate (cyan) as the
positive control. The negative control measures the ATPase activity of the denatured αlactalbumin (green) in the absence of chaperonin.

3.9 The ability of the mitochondrial hsp60 chaperonin to refold specific disease
related denatured protein
Figure 3.9 shows the ability of the various chaperonin complexes to refold denatured
malate dehydrogenase. The protein refolding activity for wild-type Hsp60/Hsp10
resulted in 70–80% refolding by comparing to the native malate dehydrogenase. In
contrast, Hsp60-V72I/Hsp10 and Hsp60-(D3G) displayed severely decreased refolding
activity. Comparing to the hsp60 wildtype, it was 100-fold lower for Hsp60-V72I/Hsp10
and Hsp60-D3G/Hsp10.
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Figure 3.8 Malate Dehydrogenase Protein Folding Assay.

This assay involves the refolding of acid-denatured malate dehydrogenase by wildtype hsp60/hsp10 (cyan), V72I mutant/hsp10 (red), D3G mutant/hsp10 (yellow). The
assay conditions are described in “Methods” section. The positive control is native
malate dehydrogenase (MDH, blue) and its activity is determined by generating a
product with absorbance at 450 nm that is proportional to the enzymatic activity present.
The negative control consists of denatured malate dehydrogenase (green) in the
absence of chaperonin.
Besides malate dehydrogenase protein, we also use the ATP synthase -subunit as
substrate for the protein folding activity. From Figure 3.10, we can get the conclusion
that the protein refolding activity of hsp60 mutant chaperonin for the denatured ATP
synthase β-subunit significantly decrease by comparing to the hsp60 wildtype. The
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single point mutation in the mitochondrial hsp60/10 chaperonin system is an indirect
cause of the neurological disorder. The two mutates are not folding the ATP synthase subunit, which in turn results in low ATP levels in-vivo.
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Figure 3.9 ATP synthase F1 β-Subunit Protein Folding Assay.
The activity of native, thermally denatured, and refolded F1 ATP synthase β-subunit by
chaperonin was detected using the EnzChek phosphate assay. The denatured β-Subunit
(green) in the absence of chaperonin served as a negative control, while the native β-Subunit
(cyan) in the absence of chaperonin served as a positive control. In the presence of α-Subunit,
refolding of denatured β-Subunit by wild-type hsp60/hsp10 (yellow), V72I mutant/hsp10
(blue), D3G mutant/hsp10 (red) was measured as described in the Methods section.
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3.10 The study of topologies of a Substrate Protein (MDH) Bound to the Human
Chaperonin Hsp60

The hydrophobic flexible C-terminal end of each subunit in the hsp60 chaperonin,
protrudes inside the central cavity.[171] The central cavity is the place where the protein
folding cycle happens.[172] We generated and characterized E. coli strains expressing
Hsp60 C-terminus deletion chaperonin protein to study the hsp60 protein folding cycle. If
the C-terminus deletion of hsp60 chaperonin impaired the interaction between
neighboring subunits, the yeast strains will dead. Researchers have showed that the Cterminus deletion hsp60 still remained capable of the binding activity with the
cochaperonin hsp10 in the nucleotide-dependent manner.[173] However, the C-terminus
hsp60 mutant cannot refold the denatured rhodanese enzyme.[174] The hydrophobic
flexible C-terminus in the hsp60 chaperonin plays an important role in the protein folding
cycle. In previous studies, the C-terminus of yeast Hsp60 chaperonin that contains
predominantly hydrophobic amino acid residues (Glycine-Glycine- Methionine repeat)
have been shown to be important for protein folding.[175]
The hsp60 homologue GroEL has been well studied for the protein folding
cycle. Researchers found that the unfolded, non-functional protein will bind to the central
cavity of the complexes via the flexible hydrophobic C-terminus end interaction.[176]
Since the high flexibility, the final 23 residues in the C-terminal region of GroEL
chaperonin are invisible in the crystal structure.[177] Machida and his colleague reported
that the KNDAAD hydrophilic residues of the final 23 residues in the C-terminus of the
GroEL within the central cavity plays a critical role in the protein folding cycle.[174] In their
study, they found that the flexible C-terminal region of GroEL chaperonin maintains a
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hydrophilic environment at the bottom of the chamber for productive protein folding. They
demonstrated an active involvement of specific hydrophilic residues within the GroEL
flexible C-terminus for the productive protein folding. During chaperonin-mediated folding,
the unfolded substrates fold spontaneously in the hydrophilic chaperonin cavity. The
flexible C-terminus of GroEL communicate between the two rings in the equatorial
domain, maintain an optimum environment for the central cavity and may control the
unfolded protein encapsulation and release.
Protein folding kinetics is a fast (microseconds) and simple process.[178] The whole
protein folding cycle may take microseconds to guarantee the cell metabolism properly.
Protein folding is driven by hydrophobic interactions through a collapse of hydrophobic
residues and then form the folded, functional structure.[179] Since protein folding process
is too fast to catch all the intermediates chaperonin structure during the kinetics cycle, it
is very challenge to achieve a high occupancy of chaperonin with unfolded substrates.
Thus, researcher mutant the amino acid to get the relative stable chaperonin complex
conformation within the substrates. Elad and his colleague mutant the amino acid D to C
in 473 position of GroEL to get the topologies of a substrate protein bound to the
chaperonin GroEL.[180]
We try to explain the mechanism of the hsp60 chaperonin protein folding cycle with
the unfolded substrates or the folded, unreleased substrates. Fang reported that the
deletion of 27 amino acid (IVDAPEP PAAAGAGGMPGGMPG MPGMM) in the Cterminus of yeast hsp60 chaperonin will cause the death of the yeast, however, with 26
amino acid deletion of C-terminus (VDAPEP PAAAGAGGMPGGMPG MPGMM) of hsp60
will not cause the death.[173] We generate the 26 amino acid deletion in the C-terminus
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of human hsp60 (Figure 3.10) to get the intermediate hsp60 chaperonin with the
unreleased substrates to explain the mechanism of the protein folding cycle in vitro. We
also used the Dynamic light scattering (DLS) to determine the size of the hsp60-CTD.
From Figure 3.11, we can see the hydrodynamic size of hsp60-CTD mutant is smaller
than the hsp60 wildtype. The reason of this is the hsp60-CTD mutant lacks 26 amino acid
in the C-terminus. We also determined the hydrodynamic size of hsp60-CTD mutant in
different condition (APO, ATP, ADP). The hydrodynamic size of hsp60-CTD mutant stays
same even with nucleotides treatment. (Figure 3.12) From that, we can draw the
conclusion that the hsp60-CTD mutant does not bind to any nucleotides. To detect
whether the hsp60 C-terminus deletion mutant has protein folding activity, we also
performed the protein folding activity of hsp60-CTD by using denatured MDH as the
substrate. (Figure 3.15) The hsp60-CTD mutant cannot renature the MDH enzyme.

Figure 3.10 The purification of hsp60 C-terminus deletion chaperonin via the ion exchange
chromatography and Size-exclusion chromatography
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Figure 3.11 The comparison of hsp60 wildtype APO with hsp60 CTD mutant APO by using
Dynamic light scattering (DLS)

Figure 3.12 The hydrodynamic size of hsp60 CTD mutant in different conditions (APO, ATP,
ADP)
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Figure 3.13 The Topologies of denatured MDH bound to the Chaperonin hsp60 C-terminus
mutant.
A) The native gel of hsp60, hsp60-CTD mutant, MDH, denatured MDH, hsp60-CTD-hsp10-MDH
complex. B) The SDS-PAGE of hsp60-CTD-MDH complex

After we got the purified hsp60-CTD mutant protein, cochaperonin hsp10 protein,
and the MDH protein, the native gel PAGE was performed to determine the size of the
hsp60-CTD-MDH complex. The size of hsp60-CTD-MDH complex is larger than the size
of hsp60-CTD without binding the substrates. (Figure 3.13 A). The DLS results also
confirmed that the size of hsp60-CTD-MDH complex is larger than the hsp60-CTD without
the substrate. (Figure 3.14) From Figure3.14, we can also get the conclusion that
nucleotide will not bind to the hsp60-CTD mutant.
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To confirm the hsp60-CTD-MDH complex, we extract the hsp60-CTD-MDH band
from the native gel, dissolve the native gel band, and run the SDS-PAGE. From the Figure
3.13 B, we can get the conclusion that the hsp60-CTD-MDH complex band that we
extracted from the native gel contains hsp60-CTD and substrate MDH.

Figure 3.14 The hydrodynamic size determinization of CTD-MDH complex
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Figure 3.15 Malate Dehydrogenase Protein Folding Assay of hsp60-CTD.

This assay involves the refolding of acid-denatured malate dehydrogenase by wildtype hsp60/hsp10 (gray), hsp60-CTD mutant/hsp10 (yellow). The assay conditions are
described in “Methods” section. The positive control is native malate dehydrogenase
(MDH, blue) and its activity is determined by generating a product with absorbance at
450 nm that is proportional to the enzymatic activity present. The negative control
consists of denatured malate dehydrogenase (carroty) in the absence of chaperonin.
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Chapter 4: Discussion

Failure to acquire proper protein-folding to create normal tertiary or quaternary
structure leads to impaired physiological functions and numerous disease conditions
[181, 182]. The working hypothesis during the studies presented here assumed that the
diseases MitCHAP-60 and SPG13 were not directly related to the hsp60 mutations but
instead were the consequence of an inactive hsp60/10 where protein folding is
diminished. To study the effects of the D3G and V72I mutations and the underlying
cause of MitCHAP-60 and SPG13, we first characterized the wild type chaperonin in
terms of conformational changes that take place during the catalytic cycle.
None of the proteins in this study were tagged to keep the proteins as close to
wild type conditions as possible. Wild type human mitochondrial hsp60 and human
mitochondrial hsp10 were expressed in E. coli and purified to near homogeneity
(Figure 1). Before any biophysical experiments were to be performed, we verified that
the proteins that were isolated were biologically active. To this end, purified hsp60 was
mixed with its co-chaperonin hsp10 in a 1:1 molar ratio before checking its ability to
refold denatured α-lactalbumin in the presence of ATP. Enzymatic activity was detected
as the release of inorganic phosphate from the hydrolysis of ATP (ATP → ADP + Pi) as
noted in the methods section. Once we established that the purified proteins were
biologically active, samples of the proteins were placed onto carbon coated grids for
negative-stain electron microscopy. The APO conformation was determined previously
in our lab and so we focused on the ATP and ADP conformations [142]. Negative stain
datasets were collected for low resolution reconstructions so that we could establish the
various conformational states of the wild type hsp60/10 chaperonin in the presence and
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absence of ATP and ADP. In previous studies in our lab, we were able to determine that
the bacteriophage chaperonin φEL will not proceed along the protein-folding pathway in
the absence of substrate and will instead stall at a conformation that is induced by either
ATP, ADP or the absence of nucleotide (APO) [183]. When we tried to use nonhydrolyzable nucleotide analogues such as AMP-PNP or ATP-γ-S to prevent
conformational heterogeneity, we found that the resulting conformational structures
were in fact different compared to the natural nucleotides ATP and ADP. For example,
the use of ATP resulted in a φEL conformation that was tetradecameric with D7
symmetry, while AMP-PNP gave a φEL conformation that was heptameric and C7
(unpublished data). It appeared the analogue mimics the ADP structure rather than the
ATP structure since the C7 heptameric conformation resulted from the addition of ADP.
We therefore determined that the nucleotide analogues were not to be trusted and were
in fact not needed since the complex was stalled in the absence of substrate anyway.
Processing of the negative stain data provided low resolution reconstructions that
reveal dramatic conformational changes that take place after ATP binding, ATP
hydrolysis, and after the removal of the ADP from the nucleotide binding pocket. The
addition of 2mM ATP to hsp60/hsp10 resulted in a reconstruction of a tetradecameric
hsp60 structure with the hsp10 co-chaperonin capping only one of the chaperonin
protein-folding chambers resulting in a so-called “bullet” conformation. The addition of
100mM ATP prompted the formation of the “American football” conformation where the
hsp10 co-chaperonin is bound to both openings to the protein-folding chambers. Just
like what was seen with the φEL chaperonin, the addition of 2mM ADP to mimic the
hydrolyzed ATP conformation resulted in a single-ring conformation where the
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chaperonin separates at the equatorial domain to produce two C7 single-rings [184]. It
was shown that the φEL separated into to single-rings to allow for the folding of viral
proteins that could not be accommodated by the host chaperonin when the
bacteriophage EL infected Pseudomonas aeruginosa. This was demonstrated to be true
the φEL chaperonin was able to refold the 116 kDa denatured β-galactosidase,
restoring its activity to normal levels [183]. It is unclear why the human hsp60/10
chaperonin utilizes the single-ring conformational intermediate since it is not able to
refold β-galactosidase (data not shown). Perhaps, it is required for the refolding of
proteins not quite as large as β-galactosidase and may utilize a mechanism similar to
the cytosolic TriC chaperonin where parts of the denatured substrate are folded
sequentially [185].
The resulting reconstructions have allowed us to postulate a likely catalytic
pathway with various conformational intermediates. The double-ring APO conformation
is unable to bind hsp10 and therefore has accessible protein-folding chambers where a
protein might be able to bind initially. Upon ATP binding, there is a conformational
change that allows not only the internalization of the substrate but the simultaneous
binding of the co-chaperonin hsp10. It is conceivable that after the binding of the first
substrate and co-chaperonin, a conformational change may trigger the binding of
substrate and co-chaperonin on the opposite hsp60 ring to form the double ring
“American football” conformation. ATP hydrolysis then triggers the separation of the two
rings at the equatorial domain and the formation of the closed single-ring hsp60/10
conformation. Subsequent removal of the ADP from the nucleotide binding site triggers
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two single-rings to come back together to form the APO conformation and the
re-initiation of the cycle.
The negative-stain reconstructions allowed for a baseline model for how the
human mitochondrial hsp60/10 chaperonin undergoes conformational changes during
the protein-folding catalytic pathway. Next, we proceeded with the characterization of
the hsp60 D3G and V72I mutants by first purifying the mutant proteins and checking for
protein folding activity using denatured α-lactalbumin as a substrate. Figure 2 illustrates
how the V72I mutant had about a third of the activity of the wild type hsp-60 protein
while the D3G mutant had only about one tenth the activity. Given these point mutations
lead to neurodegenerative disorders, it was expected that the activity be at least partly
altered.
The purified mutant proteins were then applied to carbon coated electron
microscopy grids for negative-stain data collection. Each sample was treated like the
wild type with ATP, ADP and no nucleotide to produce the APO conformation. The
results were very surprising in that only the untreated APO samples resulted in useable
data. D3G and V72I mutant hsp60 samples treated with either ATP or ADP appeared to
fall apart into monomers. The experiment was repeated an exhaustive number of times
but yielded the same results consistently. Attempts at optimizing the conditions to favor
a more stable structure all failed. We arrived at the conclusion that the mutant hsp60
tetradecameric complexes can be readily formed by self-assembly but then likely fail to
undergo the requisite conformational changes required by either ATP or ADP binding
and the complexes instead fall apart. This would also explain the loss of activity seen in
the denatured α-lactalbumin refolding experiment. These results were confirmed in
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dynamic light scattering experiments where the tetradecameric complex is detected by
the instrument at a hydrodynamic size of about 16nm. In the presence of nucleotide
(ATP or ADP), the complex at 16nm disappears and a peak appears at about 9nm. We
also analyzed the mutant amino acid positions in the hsp60 chaperonin X-ray structure.
The position three aspartic acid is in the interface of the two rings which are relatively
unstable. (Figure 4.1) This can explain why the D3G mutant will fall apart by adding
nucleotides. The position 72 amino acid valine is very close to the ATP binding pocket.
(Figure 4.2) The valine mutant into the isoleucine may cause the structure changed due
to the ATP binding pocket dysfunction, which may lead to the SPG13. The X-ray
structure analyze results are also consistent with our results that the point mutation
destabilizes the hsp60 complex.

Figure 4.1 The location of three position amino acid Aspartic Acid in the hsp60 chaperonin
ATP conformation X-ray structure
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Figure 4.2 The location of position 72 amino acid Valine in the hsp60 chaperonin ATP
conformation X-ray structure

The loss of hsp60/10 activity leads to neurodegeneration but this loss of activity
cannot be a direct cause of the symptoms displayed in the patients of these disorders. A
more likely scenario is that a mitochondrial protein that is a substrate for hsp60/10 is no
longer folded correctly and this in turn leads to neurodegeneration. In fact, hsp60/10 has
been shown to be involved in assembly of the mitochondrial ATP synthase complex
[186-188]. It is not surprising that if hsp60/10 activity is decreased resulting in an
altered ATP synthase activity, mitochondrial function would decrease, affecting muscle
and nerve tissues the most because that is where ATP is in highest demand.
The mitochondrial ATP synthase is a multi-subunit enzyme composed of two
domains, FO and F1, which together with other proteins function as a rotational motor to
allow for ATP production during respiration. The F 1 domain of the ATP synthase is
responsible for the synthesis of ATP, where the - and -subunits form a catalytically
active hexameric 33 complex. The 33 complex in isolation results in a complex that
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hydrolyzes ATP instead of synthesizing it. The D3G mutation near the hsp60 amino
terminus is thought to result in the loss of function where the D3G-hsp60 disassembles
by entropic destabilization [116]. Our work now builds on this idea by adding that the
entropic destabilization occurs through the inability to undergo normal conformational
changes and instead result in disassembly of the chaperonin. This suggests that nonfunctional hsp60/10 complexes would be unable to assemble the ATP synthase,
resulting in abnormal production of ATP inside the mitochondria. In addition, hsp60/10
and the ATP synthase -subunit, together, have been shown to be differentially
expressed in breast cancer, null cell pituitary adenoma, Barrett’s esophagus
(premalignant condition to esophageal adenocarcinoma), and head and neck squamous
cell carcinomas

[189-192]. This concomitant regulation suggests that hsp60/10 and

the ATP synthase -subunit work closely together in maintaining the cellular oxidative
phosphorylation. Defects that result in functional impairment of the mitochondrial ATP
synthase have been shown to cause a variety of neuromuscular disorders (reviewed in
[193]). Likewise, defects in mitochondrial function have also been linked to various
neurodegenerative diseases (reviewed in [194]). This led us to posit that mutations in
hsp60 lead to SPG13 and MitCHAP-60 via an inability to fold the ATP synthase subunit and other mitochondrial proteins such as malate dehydrogenase that are part of
the reactions of aerobic respiration that culminate in ATP synthesis.
The purified and reconstituted α and β subunits of the ATPase synthase selfassemble into a α33 complex that possess ATPase activity in-vitro. To investigate the
chaperonin activity of the hsp60/10 complexes, we denatured the β subunit, and
measured the ability of the hsp60/10 complexes to refold the β subunit. Renatured
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β-subunit will form a complex with the native α-subunit leading to functional complexes
with ATPase activity that can be measured via the EnzChek phosphatase assay kit. The
assay measures inorganic phosphate released from two sources, the hsp60/10
complexes catalyzing the refolding of ATP synthase -subunit and the functional α-
ATPase synthase complexes themselves (after renaturation of the β subunit). The α-
ATPase synthase complexes however hydrolyze an excess of ATP that outcompetes
that of the chaperonin. The assays in described in figures 6 and 7 confirm that the wildtype hsp60/10 can refold mitochondrial proteins involved in aerobic respiration including
malate dehydrogenase and the β-subunit of the ATP synthase. SPG13 (V72I) doesn’t
result in death because there is some residual activity as seen in Figure 7 where activity
is approximately 40% of the wild-type chaperonin activity when refolding the ATP
synthase β-subunit. MitChap60 (D3G) on the other hand has about 20% of the wild-type
chaperonin activity and results in symptoms that are more severe. This trend is
consistent with data obtained with denatured α-lactalbumin as substrate as seen in the
results section where SPG13 had 35% of wild-type activity and MitChap60 had 12% of
wild-type activity.
We also generated hsp60 C-terminus deletion mutant to study the detailed
mechanism of hsp60 protein folding cycle. We did see the hsp60-CTD and the
denatured MDH will form the hsp60-CTD-MDH complex with the ATP binding. Since
hsp60 loses the 26 amino acid C-terminus, it cannot fold the MDH properly. Our results
also showed the denatured MDH will not renatured with the help of the hsp60-CTD
mutant. However, there are still lots of unknows for the hsp60-CTD protein folding cycle.
Firstly, we have no idea whether the denatured MDH is inside the hsp60 chamber or
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just bind to the hsp60 out of the chamber. To answer this question, we will visualize the
hsp60-CTD-MDH complex by using the microscope. Secondly, the detailed substrate
binding site in the hsp60 chaperonin is also unknown. Lorimer and his colleague
reported that in GroEL chaperonin, the carbonyl oxygen of Ala109 at the C-terminus of
helix D possesses a partial negative charge that forms an electrostatic interaction
across the twofold axis with the 1-amino group of Lys105.[195] Since GroEL is the
hsp60 homolog, we hypothesis that hsp60 may perform the same substrate binding
pocket as the GroEL. However, we should get the structure of the hsp60-CTD-MDH
complex to confirm that hypothesis.

Figure 4.3 The GroEL chaperonin protein folding machine with pistons driven by ATP
binding and hydrolysis[195]
(a) A sagittal section through apo-GroEL revealing how two nucleotide-binding sites of the
different rings communicate allosterically. (b) the mechanism of how ATP binding pocket
hydrolysis ATP (c) the C-terminus salt bridge
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Chapter 5: Conclusions and Future Direction
5.1 Major conclusions

Our data suggests that hsp60/10 plays a crucial role in folding important
mitochondrial proteins involved in aerobic respiration including the -subunit of the ATP
synthase, Malate Dehydrogenase and probably several others. D3G and V72I point
mutations in hsp60 impairs the chaperonins ability to fold these substrates which in turn
leads to abnormal ATP synthesis resulting in diminished ATP levels. Minimal amounts
of ATP resulting from glycolysis and diminished ATP synthase activity can keep most
cells alive but cells with high ATP demands such as muscle and neuronal cells are
impacted more severely and explain the symptoms exhibited in the MitCHAP-60 and
SPG13 neurodegenerative disorders.

5.2 Future direction

The negative stain-EM methodology and the biological assay allowed us for the
elucidation of the human mitochondrial chaperonin in its various conformational
intermediates in the whole protein folding cycle. We could also explain the mechanism
termed MitChap60 disease and spastic paraplegia 13 by the biological assay. However,
since the limitation of resolution, we cannot get the detailed structure information of the
point mutant chaperonin hsp60 protein. For that case, crystallographic structure and
high-resolution cryo-EM structure will be the target in the future study to get the atomic
resolution structure. The atomic resolution structure of the human mitochondrional
hsp60 and its mutants will elucidate the detailed structural information to guide the
design of the drug for the neurodegenerative diseases.
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Meanwhile, we will collaborate with another research group to study the detailed
mechanism for the two neurodegenerative diseases by using fruit flies’ model in-vivo.
It seems that the mitochondrial hsp60 chaperonin is involved in the neurological
disorder indirectly. We have already found that hsp60 can fold the denature MDH and
ATPase- β subunit which involved in the ATP hydrolysis. One of our future direction will
focus on finding more substrate that involved in the neurological disorder to explain the
mechanism of the disease.
For the hsp60-CTD mutant, our future direction will focus on getting the
intermediate of the CTD-MDH complex to explain the details of hsp60 protein folding
cycle.
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Abbreviation and Notations

ATP

adenosine 5’-triphosphate

DNA

deoxyribonucleic acid

ADP

adenosine 5’-diphosphate

F1

soluble domain of ATP synthase

F0

membrane-bound domain of ATP synthase, oligomycin sensitive

kDa

Kilodalton

hsp60

60 kDa heat shock protein

E. coli

Escherichia coli

Apo

nucleotide-free, unbound state

in-vivo

within the living

EM

electron microscopy

PCR

polymerase chain reaction

T7

bacteriophage T7

T7 lac

lactose-induced, T7 RNA polymerase-specific promoter

EDTA

ethylenediaminetetraacetic acid

HPLC

high-performance liquid chromatography

pI

isoelectric point

TEM

transmission electron microscope

CTF

contrast transfer function

2D

two-dimensional

3D

three-dimensional

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

OD600

optical density, 600 nanometers

DTT

dithiothreitol, Cleland’s reagent
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FSC

Fourier shell correlation

PDB

protein databank accession code

In vitro

outside a living organism

2xTY

yeast, tryptone and salt-based growth medium

IPTG

isopropyl β-D-1-thiogalactoside

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

DNase

deoxyribonucleic acid hydrolase

AEX

anion-exchange chromatography

FF

fast flow-through

SEC

size-exclusion chromatography

BCA

bicinchoninic acid
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Appendix 1
The information of 68 types of spastic paraplegia (adapted from https://www.omim.org website)
Location Phenotype
1p36.13
1p31.1p21.1
1p13.3
1p13.2
1q32.1
1q42.13
1q42.13
2p22.3

2p11.2
2q33.1
2q37.3
3q12.2
3q25.31
3q27q28
4p16p15
4p13
4q25
6p25.1
6q23q24.1
7p22.1
7q22.1

Spastic paraplegia 78,
autosomal recessive
Spastic paraplegia 29,
autosomal dominant
Spastic paraplegia 63
Spastic paraplegia 47,
autosomal recessive
Spastic paraplegia 23
Spastic paraplegia 44,
autosomal recessive
Spastic paraplegia 74,
autosomal recessive
Spastic paraplegia 4, autosomal
dominant
Spastic paraplegia 31,
autosomal dominant
Spastic paraplegia 13,
autosomal dominant
Spastic paraplegia 30,
autosomal recessive
Spastic paraplegia 57,
autosomal recessive
Spastic paraplegia 42,
autosomal dominant
Spastic paraplegia 14,
autosomal recessive
Spastic paraplegia 38,
autosomal dominant
Spastic paraplegia 79,
autosomal recessive
Spastic paraplegia 56,
autosomal recessive
Spastic paraplegia 77,
autosomal recessive
Spastic paraplegia 25,
autosomal recessive
Spastic paraplegia 48,
autosomal recessive
Spastic paraplegia 50,
autosomal recessive

Phenotype
MIM number
617225

Gene/Locus

609727

SPG29

615686
614066

AMPD2
AP4B1

270750
613206

DSTYK
GJC2

616451

IBA57

182601

SPAST

610250

REEP1

605280

HSPD1

610357

KIF1A

615658

TFG

612539

SLC33A1

605229

SPG14

612335

SPG38

615491

UCHL1

615030

CYP2U1

617046

FARS2

608220

SPG25

613647

AP5Z1

612936

AP4M1
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ATP13A2

8p22

Spastic paraplegia 53,
autosomal recessive
8p21.1- Spastic paraplegia 37,
q13.3
autosomal dominant
8p11.23 Spastic paraplegia 18,
autosomal recessive
8p11.23 Spastic paraplegia 54,
autosomal recessive
8q12.3
Spastic paraplegia 5A,
autosomal recessive
8q24.13 Spastic paraplegia 8, autosomal
dominant
9p13.3
Spastic paraplegia 46,
autosomal recessive
9q
Spastic paraplegia 19,
autosomal dominant
10q22.1- Spastic paraplegia 27,
q24.1
autosomal recessive
10q24.1 Spastic paraplegia 9A,
autosomal dominant
10q24.1 Spastic paraplegia 9B,
autosomal recessive
10q24.1 Spastic paraplegia 64,
autosomal recessive
10q24.2 Spastic paraplegia 33,
autosomal dominant
10q24.3 Spastic paraplegia 62
1
10q24.3 Spastic paraplegia 45,
2-q24.33 autosomal recessive
11p14.1- Spastic paraplegia 41,
p11.2
autosomal dominant
11q12.3 Silver spastic paraplegia
syndrome
11q13.1 Spastic paraplegia 76,
autosomal recessive
12q13.3 Spastic paraplegia 10,
autosomal dominant
12q13.3 Spastic paraplegia 26,
autosomal recessive
12q23Spastic paraplegia 36,
q24
autosomal dominant
12q24.3 Spastic paraplegia 55,
1
autosomal recessive
13q13.3 Troyer syndrome
13q14
Spastic paraplegia 24,
autosomal recessive
14q12Spastic paraplegia 32,
q21
autosomal recessive

614898

VPS37A

611945

SPG37

611225

ERLIN2

615033

DDHD2

270800

CYP7B1

603563

WSHC5

614409

GBA2

607152

SPG19

609041

SPG27

601162

ALDH18A1

616586

ALDH18A1

615683

ENTPD1

610244

ZFYVE27

615681

ERLIN1

613162

NT5C2

613364

SPG41

270685

BSCL2

616907

CAPN1

604187

KIF5A

609195

B4GALNT1

613096

SPG36

615035

C12orf65

275900
607584

SPG20
SPG24

611252

SPG32
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14q12
14q22.1
14q22.1
14q24.1
14q32.3
1
15q11.2
15q21.1
15q21.2
15q22.3
1
16p12.3
16q23.1
16q24.3
19p13.2
19q12
19q13.1
2
19q13.3
2
19q13.3
3
Xq11.2
Xq22.2
Xq24q25
Xq28
Xq28

Spastic paraplegia 52,
autosomal recessive
Spastic paraplegia 3A,
autosomal dominant
Spastic paraplegia 28,
autosomal recessive
Spastic paraplegia 15,
autosomal recessive
Spastic paraplegia 49,
autosomal recessive
Spastic paraplegia 6, autosomal
dominant
Spastic paraplegia 11,
autosomal recessive
Spastic paraplegia 51,
autosomal recessive
Mast syndrome

614067

AP4S1

182600

ATL1

609340

DDHD1

270700

ZFYVE26

615031

TECPR2

600363

NIPA1

604360

SPG11

613744

AP4E1

248900

ACP33

Spastic paraplegia 61,
autosomal recessive
Spastic paraplegia 35,
autosomal recessive
Spastic paraplegia 7, autosomal
recessive
Spastic paraplegia 39,
autosomal recessive
Spastic paraplegia 43,
autosomal recessive
Spastic paraplegia 75,
autosomal recessive
Spastic paraplegia 12,
autosomal dominant
Spastic paraplegia 73,
autosomal dominant
Spastic paraplegia 16, X-linked,
complicated
Spastic paraplegia 2, X-linked
Spastic paraplegia 34, X-linked

615685

ARL6IP1

612319

FA2H

607259

PGN

612020

PNPLA6

615043

C19orf12

616680

MAG

604805

RTN2

616282

CPT1C

300266

SPG16

312920
300750

PLP1
SPG34

MASA syndrome
CRASH syndrome

303350
303350

L1CAM
L1CAM
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Appendix 2. The Gene Sequence of HSD1
ATGgccaaagatgtaaaatttggtgcagatgcccgagccttaatgcttcaaggtgtagaccttttagccgatgctgtggccgttacaat
ggggccaaagggaagaacagtgattattgagcagagttggggaagtcccaaagtaacaaaagatggtgtgactgttgcaaagtca
attgacttaaaagataaatacaaaaacattggagctaaacttgttcaagatgttgccaataacacaaatgaagaagctggggatggc
actaccactgctactgtactggcacgctctatagccaaggaaggcttcgagaagattagcaaaggtgctaatccagtggaaatcagg
agaggtgtgatgttagctgttgatgctgtaattgctgaacttaaaaagcagtctaaacctgtgaccacccctgaagaaattgcacaggtt
gctacgatttctgcaaacggagacaaagaaattggcaatatcatctctgatgcaatgaaaaaagttggaagaaagggtgtcatcaca
gtaaaggatggaaaaacactgaatgatgaattagaaattattgaaggcatgaagtttgatcgaggctatatttctccatactttattaatac
atcaaaaggtcagaaatgtgaattccaggatgcctatgttctgttgagtgaaaagaaaatttctagtatccagtccattgtacctgctcttg
aaattgccaatgctcaccgtaagcctttggtcataatcgctgaagatgttgatggagaagctctaagtacactcgtcttgaataggctaa
aggttggtcttcaggttgtggcagtcaaggctccagggtttggtgacaatagaaagaaccagcttaaagatatggctattgctactggtg
gtgcagtgtttggagaagagggattgaccctgaatcttgaagacgttcagcctcatgacttaggaaaagttggagaggtcattgtgacc
aaagacgatgccatgctcttaaaaggaaaaggtgacaaggctcaaattgaaaaacgtattcaagaaatcattgagcagttagatgtc
acaactagtgaatatgaaaaggaaaaactgaatgaacggcttgcaaaactttcagatggagtggctgtgctgaaggttggtgggaca
agtgatgttgaagtgaatgaaaagaaagacagagttacagatgcccttaatgctacaagagctgctgttgaagaaggcattgttttggg
agggggttgtgccctccttcgatgcattccagccttggactcattgactccagctaatgaagatcaaaaaattggtatagaaattattaaa
agaacactcaaaattccagcaatgaccattgctaagaatgcaggtgttgaaggatctttgatagttgagaaaattatgcaaagttcctca
gaagttggttatgatgctatggctggagattttgtgaatatggtggaaaaaggaatcattgacccaacaaaggttgtgagaactgctttat
tggatgctgctggtgtggcctctctgttaactacagcagaagttgtagtcacagaaattcctaaagaagagaaggaccctggaatgggt
gcaatgggtggaatgggaggtggtatgggaggtggcatgttctaa
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Appendix 3. The Map of pET-22b (+)
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